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Cardiovascular disease (CVD), defined by the World Health Organization (WHO) as 
diseases that involve the heart and/or blood vessels is the number one cause of morbidity 
and mortality worldwide. In the United States more health care dollars are spent managing 
and treating CVD and/or its complications than any other disease process. Coronary heart 
disease (CHD) is the leading cause of deaths (43.8%) attributable to CVD, followed by stroke 
(16.8%), hypertension (9.4%) and heart failure (HF) (9%). CVD-related deaths and attendant 
morbidities, which include lifelong disability are in many cases preventable. 
This research proposes a dynamic risk model that handles multi-type recurrent events 
with a dependent terminating event in a competing risk framework, specifically nonfatal MI, 
stroke and HF, with all-cause mortality (death) as the dependent terminating event. A unique 
feature of this model is that it directly quantifies the baseline hazard for each recurrent CVD 
event and death, and the additional hazard that each recurrent event confers to its own 
recurrence and all other events. Positive and negative associations and relationships between 
all event types, recurrent and terminating, are established. The baseline hazard is dynamically 
updated with each event occurrence and affected by the types and number of events up to 
that point. The model is validated with a simulation study and applied to the Antihypertensive 
and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) study. A procedure to 
assess the goodness of fit of the model is detailed.  
The model is further extended to incorporate risk factors for MI, stroke, HF and death 
such that each event type has unique risk factors [intrinsic hazards covariate model 1 (IHCM 
1)]. Risk factors for the 4 event types imparted by antecedent nonfatal events is also 
established [intrinsic and recurrent hazards covariate model (IRHCM)]. Heterogeneity of 
ALLHAT treatment arm effects (amlodipine vs chlorthalidone; lisinopril vs chlorthalidone) on 
hazards by subgroup [sex, diabetes, race (black/nonblack), age, kidney disease, atrial 
fibrillation, hypertension treated at baseline, and stage 1/stage 2 hypertension] is studied 
(IHCM 2).    
Stabilization, fine tuning and validation of the model is performed by supervised 
learning, utilizing bagged training sets (70% and 60%) and test sets (30% and 40%) of IHCM 1 
(250 bagged sets) and IRHCM (200 bagged sets, 70/30 training/test sets). Parameters are 
tuned and 95% confidence intervals (CI’s) constructed by the mean and standard deviation of 
the estimated parameters of the bagged training sets, respectively. Training set parameters 
applied to corresponding test sets yield similar and consistent goodness of fit measures for 
IHCM 1 and IRHCM, which suggests good generalization of the model without overfitting. 
Given the enormous global burden of CVD, this model is of great clinical import with 
significant potential to prevent and reduce future CVD events and develop into a risk 
assessment tool/decision rule, particularly in high-risk patients and delineate optimal 
treatment strategies tailored to the individual’s clinical profile.  
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CHAPTER 1: BACKGROUND AND SIGNIFICANCE 
Cardiovascular disease 
 
Cardiovascular disease (CVD), defined by the World Health Organization (WHO) as 
diseases that involve the heart and/or blood vessels is the number one cause of morbidity and 
mortality worldwide.1 According to WHO statistics, of the 57 million global deaths in 2008, 17.3 
million (30%) were due to CVD, of which 7.3 million were attributed to myocardial infarctions 
(MI) and 6.2 million were due to strokes.1 The impact of CVD on human health, quality of life and 
longevity cannot be overstated. In the United States alone, more health care dollars are spent 
managing and treating CVD and/or its complications than any other disease process.2 In 2015, 
2.7 million resident deaths were registered in the United States, and 10 leading causes of death, 
of which heart disease was number one and stroke was 5th, accounted for 74.2% of those deaths.2 
Coronary heart disease (CHD) is the leading cause of deaths (43.8%) attributable to CVD, followed 
by stroke (16.8%), hypertension (9.4%) and heart failure (HF) (9%). Deaths and attendant 
morbidities that arise from CVD are in many cases preventable.1,2 
According to the latest figures from the American Heart Association (AHA)2, by 2035 over 
135 million adults in the United States (45.1%) are projected to have CVD of some type, and total 
costs of CVD are expected to reach $1.1 trillion, with direct medical costs projected to reach 
$748.7 billion and indirect costs $368 billion. 
Subtypes, pathophysiology and risk factors 
 
There are two main types of CVD. The first type is due to atherosclerosis1 and includes 
coronary artery disease (CAD)/ischemic heart disease, cerebrovascular disease such as stroke, 




disease. The second type of CVD includes congenital heart disease, rheumatic heart disease, 
cardiomyopathies and cardiac arrhythmias.1-3 Atherosclerotic CVD is much more common and 
furthermore, deaths due to myocardial infarction (MI) and stroke comprise the vast majority of 
CVD deaths.1-3 The vast majority of strokes are ischemic (87%), and the remainder hemorrhagic, 
which is secondary to rupture of a blood vessel that is usually secondary to hypertension.2 
Atherosclerosis is the underlying disease process that results in MI and the vast majority 
of strokes. The pathophysiology of atherosclerosis is complex, and a brief summary will be 
presented here. Atherosclerosis is an inflammatory process that affects medium and large 
vessels.1,3 The endothelium of these vessels, when exposed to elevated levels of low-density 
lipoprotein (LDL) particles and other substances such as free radicals, becomes permeable to 
lymphocytes and monocytes. These cells migrate into the intimal layer (second layer, just below 
the endothelium) of the blood vessel. LDL particles are further attracted to this site due to a series 
of reactions, and are engulfed by the monocytes, which then transform into macrophages (foam 
cells). Smooth muscle cells migrate to the site from the tunica media (the deeper layer of the 
vessel, below the intimal layer). A fibrous cap eventually forms, consisting of smooth muscle and 
collagen. The foam cells begin to die, which forms a necrotic core that is covered by the fibrous 
cap. These lesions are known as atheromatous plaques, and they enlarge as cells and lipids 
continue to accumulate in them. The plaque begins to bulge into the vessel lumen, and as the 
process continues, the fibrous cap thins out, accompanied by fissuring of the endothelial surface 
of the plaque. This plaque may rupture, and when it does, lipid fragments and cellular debris are 
released into the vessel lumen. These fragments and debris are exposed to thrombogenic agents 




thrombus is large enough, and it results in blockage of a coronary artery or cerebral artery, it 
causes an MI or stroke, respectively.1,3 
HF occurs when an abnormality of cardiac function results in failure to provide adequate 
blood flow, or perfusion to meet the body’s metabolic needs, specifically of tissues and organs. 
HF also occurs when there is an excessive rise in cardiac filling pressures.3 In the United States, 
the leading cause of heart failure (HF) is ischemic heart disease.3 The AHA2 reports that according 
to NHANES data from 2011 to 2014, an estimated 6.5 million Americans aged 20 and above had 
HF, which is an increase from the 5.7 million reported from 2009 to 2012. AHA projects that the 
prevalence of HF will increase 46% from 2012 to 2030. In 2012, total cost for HF was an estimated 
$30.7 billion of which 68% was attributed to direct medical costs. Recurrent hospitalizations after 
HF diagnosis is a significant source of health care expenditures; additionally, physician office visits 
and ED visits for HF also contribute to costs.2 
Key ALLHAT CVD findings 
 
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial 
(ALLHAT) was a landmark clinical trial that sought to determine whether incidence of fatal CHD 
or nonfatal MI was lower for high-risk hypertensive patients treated with a calcium channel 
blocker (CCB) or an angiotensin converting enzyme (ACE) inhibitor as compared to treatment 
with chlorthalidone, a thiazide diuretic.4-6 Diuretic are less expensive than CCB’s and ACE 
inhibitors; the treatment and complications of hypertension are a significant source of health 
care costs.2 Appropriate treatment of hypertension is imperative given its significant role in CVD, 
both as a subtype of CVD and as a precipitator of other CVD processes. ALLHAT results showed 




groups, and similarly, all-cause mortality also did not differ between the treatment groups. HF 
was a secondary outcome in ALLHAT; both amlodipine and lisinopril had a higher 6-year rate of 
HF than chlorthalidone. Lisinopril had a higher 6-year rate of stroke compared to chlorthalidone 
as well. Chlorthalidone also performed well in controlling hypertension; it outperformed both 
amlodipine and lisinopril in controlling systolic blood pressure (SBP) at the 5-year mark.4 A later 
paper by Cushman et al.6 examined post-trial ALLHAT results 8-13 years post-randomization and 
found similar results for the primary endpoint of combined fatal CHD and nonfatal MI; there were 
no significant differences between the 3 treatment arms. For secondary outcomes, amlodipine 
had higher HF hazard and lisinopril had higher stroke hazard compared to chlorthalidone.6   
These important findings from ALLHAT underscore the importance of both the initial 
incidence of CVD, e.g. MI, stroke or HF, and later incidence of these disease processes in that 
individual. All three disease processes are recurrent; each individual who does not die from the 
first manifestation of the disease has the likelihood – usually an increased likelihood according 
to the natural history of the disease – of having it recur. A thorough study of MI, stroke and HF 
recurrent events in the full cohort of ALLHAT participants randomized to the 3 treatment arms 
(𝑛 = 33,357) has never been conducted. Such a study would yield valuable insight into the 
optimal treatment and important risk factors for high-risk hypertensive individuals - not only to 
prevent the first occurrence of disease, but also to prevent further recurrences and ultimately, 
death. 
Multi-type recurrent events 
 
 The statistical methodology and analysis of recurrent events in survival and longitudinal 




event of interest can occur more than once in the same individual under observation. Multi-type 
recurrent events refer to the situation in which more than one particular event type can occur in 
the same individual, and that event type can occur more than once. These multiple types of 
recurrent events may or may not be associated, or correlated with one another.7 Additionally, 
multi-type recurrent events may have an accompanying terminal event, such as death, after 
which no further events can occur. This terminal event may or may not be related to the recurrent 
events.7  
Cook and Lawless7 included a chapter on various approaches for multi-type recurrent 
events, including intensity-based models, random effects models, rate and mean functions, and 
multistate models. These models can be extended to the multivariate case to include covariates 
associated with the events themselves, and which may explain relationships between the 
different event types. Furthermore, these models can also be extended to handle a dependent 
or independent terminal event. Intensity-based models are flexible; they can be modified to 
capture possible associations between multiple event types if event types are related, and to 
potentially handle multiple event types in conjunction with a co-occurring dependent 
termination process such as death. However, the authors suggest that parsimonious models are 
preferred in this context so the number of covariates may be limited and characterizing the 
associations between event types can be challenging. Random effects models are also flexible, 
but may require some specification of the variance-covariance matrix of the component random 
effects to describe associations between different event types, and may prove challenging to 




not ideal for multi-type recurrent events as too many states are likely to appear which 
significantly increases computational burden.7  
Numerous authors have proposed and utilized recurrent events models in various clinical 
settings for single-type and multi-type recurrent events with and without (possibly dependent) 
termination. Clegg, Cai and Sen8 proposed a multivariate marginal mixed baseline hazards model 
and applied the model to analyze two types of recurrent events: coronary heart disease (CHD) 
and cerebrovascular accident (CVA) in individuals from the Framingham Heart Study. The 
sampling unit was a cluster, i.e. family unit (for example, a married couple with children). The 
study utilized different baseline hazards for recurrent events CHD and CVA, and identical baseline 
hazard for siblings. A strength of the study was the ability to avoid imposing specific dependence 
structures on the different recurrent event types that are usually required in most frailty models. 
However, an important drawback of this model and study is that it did not account for death as 
a dependent termination event 8; both CHD and CVA are known to increase mortality.1-3  
Mazroui et al.9 utilized a multivariate frailty model for two types of recurrent events and 
their association with each other, and with a dependent terminal event in the setting of breast 
cancer. They proposed two estimation models for their model: likelihood maximization for 
models with a parametric piecewise constant baseline hazard function and maximization of the 
penalized likelihood for models with baseline hazard functions approximated by M-splines. The 
two recurrent event types were locoregional and metastatic relapse after breast cancer 
diagnosis. A major strength of their model is that the two recurrent event processes may not be 
independent or conditional on frailties and covariates; thus, the related processes of the two 




the dependent, terminating event. Details of their parameter estimation procedures and model 
diagnostics/validation can be found in the paper.9  
Zhu et al.10 proposed a joint modeling approach of semiparametric transformation 
models that was an extension of previous models for univariate recurrent and terminal events, 
to handle multivariate, multi-type recurrent events in the setting of a dependent terminal event. 
The EM algorithm was utilized for maximum likelihood estimation of parameters. They applied 
their model in the setting of childhood cancer survival, with the two recurrent event types being 
(1) recurrence of the original cancer and (2) occurrence of new cancers, and death being the 
dependent terminal event. Cai and Shaubel11 developed a class of semi-parametric marginal 
means/rates regression models for multi-type recurrent events (hospitalizations and physician 
office visits) in the setting of childhood asthma outcomes; however, their model does not account 
for a potentially dependent terminal event, nor provide inferences on the possible correlation 
structures between event types.  
Chen and Cook12 utilized cumulative mean functions for multi-type recurrent events with 
dependent termination (death) by conducting separate marginal analyses, with each analysis 
focusing on one recurrent event type. They applied their methods to patients with breast cancer 
metastasis to bone experiencing multiple types of skeletal complications, and the effect of 
bisphosphonate therapy on such recurrences. A subsequent paper by Chen et al.13 developed 
methods based on marginal models for multi-type interval-censored recurrent events, i.e. when 
the precise event times are unobserved, but the event is known to have occurred within a certain 




For single-type recurrent events approaches in multiple clinical scenarios, we refer to 
Chang, Chan and Kapadia 14; Lin, Wei, Yang, et al.15 Ghosh and Lin 16; Liu, Wolfe and Huang 17; Yu 
and Liu 18; Belot, Rondeau, Remontet, et al.19 and Maugen, Rachet, Mathoulin-Pelissier, et al.20  
Recurrent events in CVD 
 
There are very few studies that examine the multi-type recurrent events process with 
death as the dependent terminal event in the important clinical setting of cardiovascular disease. 
A recent paper by Lin, Luo, Chen, et al.21 proposed a model that handles multi-type recurrent 
events with dependent termination in the setting of cardiovascular disease on a smaller subset 
of the ALLHAT clinical trial (ALLHAT-LLT). Theirs is a multivariate joint frailty model with 
nonparametric covariate functions in a Bayesian inference framework. They used the cubic-B-
spline basis for their nonparametric covariate functions, and Bayesian inference based on Markov 
Chain Monte Carlo (MCMC) to estimate the parameters.  They compared the performance of 
three models in simulation studies: the joint model, the reduced model (the recurrent and 
terminal events were modeled independently) and the parametric model (the nonparametric 
covariate functions were modeled as linear functions). For their datasets, they generated two 
types of recurrent events and a terminal event in two different simulation settings. For simulation 
setting I there was no correlation between multi-type recurrent events and the terminal event. 
For setting II there was a positive correlation between recurrent events and the terminal event 
such that the subjects with higher risks of recurrent events were at higher risk of the terminal 
event. The joint model performed well in both simulation settings; in the first setting of 
independent termination (consistent with the reduced model), the joint model performed 




model markedly outperformed the reduced model. The joint and reduced models outperformed 
the parametric models in both simulation settings. When they applied all three models to the 
ALLHAT-LLT data, the models’ performances were similar to that of the simulations. Their key 
findings included significant positive correlation between risk of CHD and stroke, and risk of CHD 
and heart failure conditional on the observed risk factors. This suggests that subjects with one 
type of CVD event are very likely to experience another type of CVD as compared to those 
without. They also found that risks of recurrent CHD were positively associated with death/all-
cause mortality conditional on the observed risk factors, although stroke and HF did not show 
significant correlation with death. For further details on their statistical models, simulation 
studies and ALLHAT-LLT results, we refer to Lin, Luo, Chen, et al.21   
We wanted to develop a new statistical model for multi-type recurrent events with a 
dependent terminal event that can characterize the possible relationships between the different 
event types and the relationship of each event type with the terminal event. Furthermore, we 
wanted our model to be easily extended to the multivariate case such that covariates can be 
included. We aim for our model to be straightforward in its derivation and implementation, and 
flexible and adaptable to a variety of clinical settings. Our proposed statistical model is motivated 
by the ALLHAT clinical trial, specifically the in-trial cohort randomized to the treatment arms 
chlorthalidone, amlodipine and lisinopril.4,5 
Public health and clinical significance  
 
 CVD is one of the most important clinical and public health problems of our time, bar 
none. Prevention of CVD by identifying important risk factors and optimal treatment strategies 




disease and mortality, both globally and right here in the United States. Health care costs of CVD 
would be reduced in a significant way. A key component of CVD prevention and effective 
management is to not only reduce the incidence of first disease, but also recurrent disease 
processes that are related to the first. MI and stroke are acute, often severe and life-threatening 
manifestations of CVD that have an underlying, shared component of atherosclerosis, upon 
which plaque rupture and the subsequent cascade of events that leads to thrombus formation in 
the artery is the precipitating event.1,3 HF is known to have MI and coronary heart disease (CHD) 
as one of its main causes 3 and is a chronic disease process with acute exacerbations that may be 
severe and life-threatening. We believe that studying these three particular related disease 
processes that are recurring and comprise such a huge portion of CVD burden in the statistical 
framework of multi-type recurrent events with dependent termination, in this case death i.e. all-
cause mortality, is urgently needed.  
Aims and objectives  
 
Aim 1: To derive and develop a statistical model to describe dynamic risk of multi-type recurrent 
events in a competing risk framework. 
Aim 2: Apply the model specifically to examine the competing risks of three types of recurrent 
CVD events: MI, stroke, and heart failure (HF) in the ALLHAT dataset and the dependent 
terminating event, death.      
Aim 3: Utilize the model to identify and quantify important clinical risk factors and treatment 
options for each of the three multi-type recurrent events, and death. 
Aim 4: Develop a supervised learning approach for parameter tuning with variable selection, 




CHAPTER 2: JOURNAL ARTICLE 1 
A dynamic competing risk model for multi-type recurrent events with dependent termination 
Abstract 
 
Multi-type recurrent events are a common feature of longitudinal studies. In many cases, there 
is a terminating event such as death, after which no further events can occur. The terminating 
event may or may not be associated with the recurrent events. We propose a dynamic risk model 
that handles multi-type recurrent events with a dependent terminating event in a competing risk 
framework. A unique feature of our model is that it directly provides the baseline hazard for each 
type of recurrent event and the terminating event, and the additional hazard that each recurrent 
event confers to all other events. In this manner, positive and negative associations and 
relationships between all event types, recurrent and terminating, are established. The baseline 
hazard is dynamically updated with each event occurrence, and is affected by event history (the 
number and types of past events) and covariates. We validate our model with a simulation study. 
The model is applied to the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart 
Attack Trial (ALLHAT) study and the findings described. Furthermore, a procedure developed to 
assess goodness of fit of the model is detailed. We provide a discussion of the results and their 
clinical implications. 






1.  Introduction 
 
Recurrent events, where one or more types of events can occur repeatedly in the same individual 
are a common feature of longitudinal studies. Examples of single-type recurrent events include 
cancer relapses, chronic obstructive pulmonary disease (COPD) exacerbations, recurring 
opportunistic infections and recurrent heart failure (HF) episodes. Multi-type recurrent events 
refer to the situation in which more than one particular event type can occur in the same 
individual, and that event type can occur more than once. Such multiple types of recurrent events 
may or may not be associated or correlated with one another. In both single-type and multi-type 
recurrent events, death from any cause will be a terminating event after which no further events 
can occur. The terminating event may be associated with preceding events; for example, it is 
known that nonfatal myocardial infarction (MI), nonfatal stroke and nonfatal HF individually 
increase the risk of subsequent death.1  
Recurrent events models are widely reported in the literature. For single-type recurrent 
events models in various clinical scenarios, we highlight the works of Lin et al.,2 Chang et al.,3 
Ghosh and Lin,4 Liu et al.,5 Yu and Liu,6 Belot et al.7 and Maugen et al.8 For multi-type recurrent 
events, Cook and Lawless9 included a chapter on various approaches, including intensity-based 
models, random effects models, rate and mean functions, and multistate models. An important 
aspect of multi-type recurrent events models in particular is their ability to characterize potential 
associations between recurrent events; an event can increase the risk of a subsequent event of 
the same type, or of a different type, or both. Furthermore, such a model should also characterize 




In clinical contexts, the dependent terminal event is usually death. We briefly mention several 
models that meet these demands here. 
Zhu et al.10 proposed a joint modeling approach of semiparametric transformation 
models that was an extension of previous models for univariate recurrent and terminal events, 
in the setting of childhood cancer survival with the two recurrent event types being recurrence 
of the original cancer and occurrence of new cancers, and death being the dependent terminal 
event. Mazroui et al.11 utilized a multivariate frailty model for two types of recurrent events and 
their association with each other, with death as the dependent terminal event in the setting of 
breast cancer. Lin et al.12 proposed a multivariate joint frailty model with nonparametric 
covariate functions in a Bayesian inference framework that handles coronary heart disease 
(CHD), stroke and HF as multi-type recurrent events with death as the dependent terminating 
event. 
 The baseline hazards of events, including recurrent events are often of significant interest 
in longitudinal studies. The semi-parametric Cox proportional hazards model reduces to the 
product limit estimate in the case of no covariates, which provides an estimate of the baseline 
hazard function as a straightforward transformation of the survival function.13 Breslow14 
provided a similar estimate. However, these approaches do not address baseline hazard 
functions for recurrent events. Furthermore, parametric baseline hazard functions for recurrent 
events may be desired in certain situations. To our knowledge, there has not been to date a multi-
type recurrent events model that can accomplish the following: 1) directly quantify the specific 
baseline hazard, or absolute risk, that each nonfatal event confers on itself to recur, every other 




2) update the baseline hazard of every nonfatal event and death with the occurrence of each 
nonfatal event; 3) express the dynamic risk of each nonfatal event and death as an accumulation 
of separate, unique baseline hazards that arise from the event history, which yields new 
information and insights into the clinical problem being studied. In this paper, we show that our 
model, motivated by the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack 
Trial (ALLHAT) study meets these objectives and several additional ones. Throughout this paper, 
we will use the terms hazard and risk interchangeably. 
  The remainder of this paper is organized as follows. In Section 2, we introduce our multi-
type recurrent events model with a dependent terminal event.  Statistical inference of the model 
parameters and numerical approaches are described in Section 3. In Section 4, we present a 
simulation study that validates our estimation methods. Section 5 details the application of our 
model to the landmark ALLHAT clinical trial. We provide discussion of our results and state our 
conclusions in Section 6.  
2.  Model 
 
2.1 Model Formulation  
 
Let 𝑇𝑀, 𝑇𝑆, 𝑇𝐻 and 𝑇𝐷 be the times at which the next MI, stroke, HF episode (henceforth referred 
to as HF and all of these events will be assumed to be nonfatal) and death from any cause 
(henceforth death) occur, respectively; specifically: 𝑇𝑀, 𝑇𝑆, 𝑇𝐻 and 𝑇𝐷 represent the times elapsed 
from the time point of interest. We assume that (1) two or more events cannot occur 
simultaneously, i.e. in an infinitesimally small time interval ∆𝑡 only one event can occur; (2) the 




and types of events up to the current time. From (1), for any event type 𝑤 (where 𝑤 represents 
MI, stroke, HF or death) and 𝑊 the number of event types, 
𝑃(𝑡 < 𝑇𝑤 < 𝑡 + ∆𝑡|ℎ𝑖𝑠𝑡𝑜𝑟𝑦 𝑢𝑝 𝑡𝑜 𝑡) = 𝛼𝑤∆𝑡 + 𝑜(∆𝑡)  for  𝑤 = 1, … , 𝑊 




We let 𝑠(𝑡) = 𝑃(𝑇𝑀 > 𝑡,  𝑇𝑆 > 𝑡, 𝑇𝐻 > 𝑡, 𝑇𝐷 > 𝑡) 
Then, 
𝑠′(𝑡) = 𝑠(𝑡)(−𝛼𝑀−𝛼𝑆−𝛼𝐻−𝛼𝐷) 
or equivalently, 
𝑠(𝑡) = 𝑒−(𝛼𝑀+𝛼𝑆+𝛼𝐻+𝛼𝐷)𝑡 
where 𝑠(𝑡) represents event-free survival of duration 𝑡, 𝑡 ≥ 0; and 𝛼𝑀 , 𝛼𝑆, 𝛼𝐻 and 𝛼𝐷 represent 
the hazard of the next MI, stroke, HF and death, respectively. 
We formulate our model on the basis of the above results. The hazards 𝛼𝑀, 𝛼𝑆, 𝛼𝐻 and 
𝛼𝐷 for each individual are assumed to be dependent on that individual’s event history. A 
reasonable rationale for that dependence structure is to assume that there is an intrinsic hazard 
for each event (MI, stroke, HF and death). Each nonfatal event then imposes an additional hazard 
to itself (its own recurrence) and an additional, almost certainly different, hazard to each of the 
other two nonfatal events and death. Death, being the terminal event, has its own intrinsic 
hazard plus additional hazards accrued from any nonfatal events (MI, stroke, HF) that have 
occurred in an individual’s event history. 
Our model therefore updates the hazards 𝛼𝑀 , 𝛼𝑆, 𝛼𝐻 , and 𝛼𝐷 dynamically as nonfatal 
























































(𝑡)𝜷𝑫𝑯𝑝𝑖𝑗                                   
(1) 
 
where 𝑚𝑖𝑗, 𝑛𝑖𝑗, and  𝑝𝑖𝑗 represent the total number of MI’s, strokes and HF’s, respectively that 
have occurred prior to event time 𝑡𝑖𝑗; 𝑡𝑖𝑗 denotes the time of the 𝑗
𝑡ℎ event in the 𝑖𝑡ℎ individual. 
Our model postulates two main types of hazards: intrinsic and event-type. The intrinsic hazards 
for MI, stroke, HF and death are expressed by regression covariate coefficient vectors 𝝁𝑴, 𝝁𝑺, 𝝁𝑯 
and 𝝁𝑫 associated with covariate vectors 𝑿𝑴𝒊(𝑡), 𝑿𝑺𝒊(𝑡), 𝑿𝑯𝒊(𝑡) and 𝑿𝑫𝒊(𝑡), respectively. These 
intrinsic hazards are the underlying hazards every individual has for MI, stroke, HF and death. The 
recurrent parameters denoted by regression covariate coefficient vectors 𝜷𝑴𝑴, … , 𝜷𝑫𝑯 and 
associated with covariate vectors 𝑿𝑴𝑴𝒊(𝑡), … , 𝑿𝑫𝑯𝒊(𝑡) represent the event-type hazards, i.e. the 
additional hazard for a particular event, nonfatal or fatal, conferred by a particular preceding 
nonfatal event. Thus, 𝑿′• 𝑴𝒊(𝑡)𝜷• 𝑴 is the additional hazard for any event type (MI, stroke, HF or 
death) conferred by preceding MI specifically in the 𝑖th individual with covariates 𝑿• 𝑴𝒊(𝑡);  
𝑿′• 𝑺𝒊(𝑡)𝜷• 𝑺 is the additional hazard for any event type (MI, stroke, HF or death) conferred by 
preceding stroke specifically in the 𝑖th individual with covariates 𝑿• 𝑺𝒊(𝑡), and so on. The covariate 
vectors are unique to each hazard type and may be time dependent. 
2.2 Likelihood function 
 












𝑖=1       (2)  
 
where 𝑖 = 1, … , 𝑛; such that 𝑛 represents the number of individuals; 𝑗 = 1, … , 𝑘𝑖, where 𝑘𝑖  
denotes the total number of events for the 𝑖𝑡ℎindividual; 𝑡𝑖𝑗 denotes the 𝑗
𝑡ℎ event time for the 
𝑖𝑡ℎ individual such that 𝑡𝑖𝑗 −  𝑡𝑖,𝑗−1 is the inter-event, or gap time between two successive events 
for the 𝑖𝑡ℎ individual; 𝐼𝑀𝑖,𝑗  is an indicator variable that denotes whether or not MI occurs at 𝑡𝑖,𝑗; 
𝐼𝑆𝑖,𝑗  is an indicator variable that denotes whether or not stroke occurs at 𝑡𝑖,𝑗; 𝐼𝐻𝑖,𝑗  is an indicator 
variable that denotes whether or not HF occurs at 𝑡𝑖,𝑗; 𝐼𝐷𝑖,𝑗 is an indicator variable that denotes 
whether or not death occurs at 𝑡𝑖,𝑗. 
3.  Estimation 
 
A modified Newton-Raphson algorithm is used to obtain the maximum likelihood estimates of 
the parameters.  For computational ease and efficiency, we derived the analytical gradients and 
hessian matrix from the log likelihood function. We controlled the step size of every iteration to 
ensure that our parameter values stayed within range; each step size was multiplied by 𝑐 starting 
with a small value for 𝑐 and gradually increasing 𝑐 closer to 1 as the step size shrank with 
increasing iterations. With this approach, we gained the benefits of faster convergence with 
Newton-Raphson while avoiding its common pitfalls of cycling, non-convergence or convergence 
to the wrong roots. From the hessian matrix at the converged values, we subsequently obtained 
the standard errors of our parameter estimates and the corresponding 95% Wald confidence 
intervals (CI) of the estimates.  





We conducted a simulation study by simulating datasets comprised of three treatment arms, 
mimicking the chlorthalidone, amlodipine, and lisinopril treatment arms from ALLHAT (described 
in detail in Section 5) and estimating the parameters. We utilized the regression parameter values 
estimated from the ALLHAT data (which we report in Section 5) as the true parameter values for 
our simulation study.  
 To simulate each dataset, we first simulated the initial gap time between time 0 
(equivalent to randomization time, with each observation assumed to have no prior events) and 
the first event as the 𝑖𝑖𝑑 exponential distribution with rate parameter 𝜆𝑜 equal to the sum of the 
intrinsic hazards for each event, i.e. 














 and mean 
1
𝜆𝑜
, where 𝑿′𝑴𝒊(𝑡) = 𝑿
′
𝑺𝒊
(𝑡) = 𝑿′𝑯𝒊(𝑡) = 𝑿
′
𝑫𝒊
(𝑡) = [1, 𝐼𝐴𝑚𝑙𝑜𝑑𝑖𝑝𝑖𝑛𝑒𝑖 , 𝐼𝐿𝑖𝑠𝑖𝑛𝑜𝑝𝑟𝑖𝑙𝑖]; 
𝐼𝐴𝑚𝑙𝑜𝑑𝑖𝑝𝑖𝑛𝑒𝑖 and 𝐼𝐿𝑖𝑠𝑖𝑛𝑜𝑝𝑟𝑖𝑙𝑖 are indicator variables that denote whether or not the 𝑖th individual 
is in the amlodipine or lisinopril treatment arms, respectively. The reference group in this 
scenario is the chlorthalidone arm. At the end of this initial gap time, we simulated the first event 
as a single random sample from a multinomial distribution, with each event type probability 





















If a nonfatal event (MI, stroke or HF) occurred, the next gap time (event-free survival) followed 
the exponential distribution with updated rate parameter 𝜆1 in accordance with the increased 
risk that arose from the new event in the manner described by (1) in Section 2. The subsequent 
event was simulated in the same manner as the first, with its event probability equivalent to its 
updated relative proportion. The relevant time units for the simulation study are in years. 
For each observation, this process continued until death or noninformative right 
censoring intervened. We chose a study endpoint 𝑌 = 8 such that each observation in the 
simulated dataset that remained alive was automatically right censored at that time. 
Furthermore, we simulated another form of noninformative censoring for each observation as 
an independent exponential distribution with a separate rate parameter 𝜆𝑐 = 0.05; this 
represented study drop-out. Therefore, total follow up time of each observation was 
min (𝑇𝐶 , 𝑇𝐷 , 𝑌) where 𝑇𝐶  represents the noninformative censoring time (study drop-out) that 
arises from 𝑖𝑖𝑑 exp (𝜆𝑐), 𝑇𝐷 represents the time of death if it occurred in the individual, and 𝑌 
represents the end of the study. We simulated 501 datasets with the first discarded as burn-in to 
yield 500 datasets, each with 30,000 observations (10,000 observations each for chlorthalidone, 
amlodipine and lisinopril). We estimated the parameters for each dataset as described in Section 
3. 
 Our simulation study results are in Table 1. For each parameter, we computed the bias as 
the average of its estimated parameters minus the true value; the standard error (SE) as the 




estimated parameters; and the coverage probability (CP) as the proportion of the simulation runs 
whose 95% CI covers the true parameter value. Our results show that the bias is small, the SE of 
each parameter is close or equal to the SD and the CP for every parameter is near or at the 
nominal value of 95%.  
5.  Application to ALLHAT 
 
5.1 Study population  
 
The details of ALLHAT’s study population have been described elsewhere.15-20 Briefly, ALLHAT 
was a double-blind, randomized controlled trial that was conducted from February 1994 through 
March 2002. Participants were aged 55 or older with hypertension and at least one other 
cardiovascular disease (CVD) risk factor (including previous [> 6 months] MI or stroke, left 
ventricular hypertrophy [LVH], history of Type 2 diabetes, current cigarette smoking, HDL < 35 
mg/dl, or documentation of other atherosclerotic CVD) from 623 centers in North America, 
specifically the United States, Canada, Puerto Rico and the US Virgin Islands. A total of 33,357 
individuals were randomized to one of three treatment arms: chlorthalidone (𝑁 = 15,255), 
amlodipine (𝑁 = 9,048) and lisinopril (𝑁 = 9,054) for planned follow-up of approximately 4 to 
8 years. Mean follow-up time was 4.9 years. The primary endpoint was combined: fatal CHD or 
nonfatal MI. Major pre-specified secondary outcomes were all-cause mortality, fatal and nonfatal 
stroke, combined CHD (the primary outcome, coronary revascularization, and hospitalized 
angina), and combined CVD (combined CHD, stroke, other treated angina, HF [fatal, hospitalized, 
or treated non-hospitalized] and peripheral arterial disease). ALLHAT was designed to determine 
whether the occurrence of fatal CHD or nonfatal MI (the primary endpoint) is lower for high-risk 




inhibitor (lisinopril), each compared to diuretic treatment (chlorthalidone).15-18 A fourth 
treatment arm, the α-blocker doxazosin was terminated early when it became apparent that 
doxazosin had a very low (< 0.05) probability of having a statistically significant lower incidence 
of the primary endpoint compared to chlorthalidone at the end of the study based on the data 
up to that point. A second reason was that a large excess of HF became evident in the doxazosin 
arm as compared to chlorthalidone.19,20 
 We applied our method to the in-trial ALLHAT dataset (𝑁 = 33,357) for the nonfatal, 
potentially recurrent events MI, stroke and HF, and death as the terminating event. Each 
observation in the dataset contained the event times in years from the date of randomization to 
the event. If multiple events occurred during the same visit or hospitalization, or within the same 
day, for which no further resolution with respect to exact event times was possible, we elected 
to assign 0.001 years (8.77 hours) of elapsed time between the two events. With respect to event 
order, we assumed that MI preceded HF and stroke, and stroke preceded HF; HF is a common 
sequela of MI both acutely and in the long-term. We estimated the parameters and their 
attendant standard errors for three different models: (1) base (intercept only) model; (2) intrinsic 
hazards covariate model; and (3) intrinsic and recurrent hazards covariate model. We did so using 
the statistical inference described in Section 3. We will hereafter refer to the base model, intrinsic 
hazards covariate model, and intrinsic and recurrent hazards covariate model as BM, IHCM and 
IRHCM, respectively.    
 5.2 ALLHAT Results  
Table 2 displays results for the BM. The intrinsic parameters are all positive and statistically 




The intrinsic hazard for death is highest (0.0273 [0.0264 - 0.0281]), more than twice the intrinsic 
hazard of MI (0.0106 [0.0101 - 0.0111]), which in turn is higher than HF (0.0066 [0.0062 - 0.0070]) 
and stroke (0.0063 [0.0059 - 0.0067]). The recurrent parameters are all positive and statistically 
significant, implying that each nonfatal event increases the hazard of every event type. For MI, 
the recurrent parameter 𝜷𝑀𝑀 is higher (0.0559 [0.0492 - 0.0627]) than 𝜷𝑀𝑆 (0.0127 [0.0070 - 
0.0183]) and 𝜷𝑀𝐻 (0.0154 [0.0102 - 0.0206]). Thus, the risk that a preceding MI imparts to future 
MI is higher than the risk that a preceding stroke or HF imparts to future MI. Similarly, the 
recurrent parameter 𝜷𝑆𝑆 is much higher (0.0249 [0.0186 - 0.0312]) than 𝜷𝑆𝑀 (0.0038 [0.0014 - 
0.0063]) and 𝜷𝑆𝐻 (0.0049 [0.0018 - 0.0080]). Thus, antecedent stroke imparts a higher risk to 
future stroke than it does to future MI or HF. The same trend continues for HF; the recurrent 
parameter 𝜷𝐻𝐻 is higher (0.1270 [0.1155 - 0.1384]) than 𝜷𝐻𝑀 (0.0584 [0.0514 - 0.0654]) and 
much higher than 𝜷𝐻𝑆 (0.0150 [0.0094 - 0.0205]). Overall, each of these nonfatal events imparts 
the greatest risk to its own recurrence, and smaller, but still significant, risks to future occurrence 
of other event types. For death, preceding HF imparts the greatest risk (0.0730 [0.0634 - 0.0826]), 
followed by stroke (0.0533 [0.0430 - 0.0635]) and then MI (0.0146 [0.0092 - 0.0199]). 
Our results for the IHCM are in Table 3. For this model, we introduced the treatment arms 
chlorthalidone, amlodipine and lisinopril for the intrinsic hazards and report the results for 
chlorthalidone and lisinopril as the reference group, respectively. In both situations, the intercept 
parameter corresponds to the intrinsic hazard for that event in the reference group (either 
chlorthalidone or lisinopril). Two indicator variables correspond to the remaining two treatment 
arms; the covariate parameters of the two indicator variables corresponding to the treatment 




excess hazard may be positive or negative. The sum of the excess hazard and the intrinsic hazard 
of the reference group yields the intrinsic hazard for that treatment arm. In this manner, we 
compare the results for amlodipine vs chlorthalidone (A vs C), lisinopril vs chlorthalidone (L vs C) 
and amlodipine vs lisinopril (A vs L). We provide the intrinsic baseline hazards for all three 
treatment arms in the leftmost column. Moreover, we chose to report the excess hazard for the 
non-reference group treatment arms this way in order to clearly show whether or not the 
difference in the two treatment arms’ hazards from that of the reference group was statistically 
significant. Of note, we have omitted the excess hazard for chlorthalidone over lisinopril (C vs L), 
because the excess hazard for lisinopril over chlorthalidone (L vs C) is already provided. 
With chlorthalidone as the reference group (A vs C and L vs C), we found that the 
amlodipine treatment arm has a significant, positive excess intrinsic hazard for HF (0.0029 
[0.0019, 0.0039]) over the chlorthalidone treatment arm. With lisinopril as the reference group 
(A vs L), the amlodipine arm has a significant, negative excess intrinsic hazard for stroke (-0.0014 
[-0.0024, -0.0003]), and a significant, positive excess intrinsic hazard for HF (0.0021 [0.0009, 
0.0033]) over lisinopril. As expected, the recurrent parameters, corresponding to the additional 
hazards contributed by preceding nonfatal events, remain essentially unchanged from the BM. 
Our results for the IRHCM are shown in Table 4. For this model, we introduced the 
treatment arms chlorthalidone, amlodipine and lisinopril for both the intrinsic hazards and 
recurrent hazards, and we again report the results for chlorthalidone and lisinopril as the 
reference group, respectively in a manner analogous to that described for the IHCM.  
With chlorthalidone as the reference group (A vs C and L vs C), the amlodipine arm had a 




The lisinopril arm had a significant, positive excess hazard for stroke conferred by an antecedent 
MI (0.0097 [0.0023, 0.0170]) over chlorthalidone. The lisinopril arm also had a significant, 
negative excess hazard for HF conferred by a preceding HF (-0.0337 [-0.0614, -0.0059]) over 
chlorthalidone. With lisinopril as the reference group (A vs L), the amlodipine arm had a 
significant, negative excess intrinsic hazard for stroke (-0.0013 [-0.0024, -0.0002]) over lisinopril. 
The amlodipine arm had a significant, negative excess hazard for stroke conferred by an 
antecedent MI (-0.0086 [-0.0164, -0.0008]) over lisinopril. The amlodipine arm also had a 
significant, positive excess intrinsic hazard for HF (0.0021 [0.0009, 0.0033]) over lisinopril.  
Overall, the IRHCM shows that the amlodipine arm had a significantly higher intrinsic 
hazard for HF than both the chlorthalidone and lisinopril arms. The lisinopril arm had a 
significantly higher intrinsic hazard for stroke than the amlodipine arm. These two results mirror 
that of the IHCM. Moreover, the lisinopril arm had a significantly higher hazard for stroke 
conferred by an antecedent MI than both the chlorthalidone and the amlodipine arms. Finally, 
the lisinopril arm had a significantly lower hazard for HF conferred by a preceding HF than the 
chlorthalidone arm. 
5.3 Model Selection and Goodness of Fit 
We chose to utilize the Akaike information criterion (AIC) to assess the quality of our models 
relative to one another. We present the AIC for all three models in Table 5. The IHCM had the 
lowest AIC, followed by the IRHCM; the BM had the highest AIC. These results suggest that the 
IHCM provides a better fit to the data than the BM or the IRHCM. The BM performs the least, 




 We also wanted to assess our models’ dynamic predictive capabilities, specifically their 
ability to predict future event occurrence as events accrue over time. For each model, we chose 
to predict event-free survival at 1-year, 2-year, 3-year and 4-year increments for all observations 
at baseline (𝑁 = 33,357), observations that had 1 or more events (𝑁 = 3,631), observations 
that had 2 or more events (𝑁 = 1,015), observations that had 3 or more events (𝑁 = 392) and 
observations that had 4 or more events (𝑁 = 155). Our dataset contained the true survival for 
that observation (i.e. a binary result of whether or not that individual had any event, nonfatal or 
fatal, within that time frame). We subsequently obtained the estimated area under the curve 
(AUC) and its standard error of the resulting receiver operating characteristic (ROC) curve for 
each time frame and number of events. If an observation was censored within the time frame of 
interest such that true survival for that time frame could not be established, we sampled from a 
Bernoulli (𝑝) distribution, with 𝑝 equal to the model’s predicted probability of survival for that 
observation. We assigned the resulting value (1 = event-free survival, 0 = event occurred) to that 
observation and repeated the sampling process for a total of 100 samples. We then averaged the 
AUC estimates and their standard errors to arrive at a final estimated AUC and standard error. 
The results for the BM, the IHCM and the IRHCM are presented in Tables 7, 8 and 9, respectively. 
The corresponding number and percentage of censored observations is provided in Table 6.   
 As the BM contains no covariates, all of the observations at baseline (0 events) have the 
same probability of event-free survival for any given time frame, which yields a fixed AUC of 0.50 
for the 1-year, 2-year, 3-year and 4-year time points. For individuals with 1+ events, there is a 
statistically significant increase in AUC (0.58 [0.56, 0.60]) at year 1 which persists to the 4-year 




(0.52, 0.59]) from the 1+ individuals, but it catches up by the 3-year mark (0.58 [0.54, 0.62]) and 
persists at the 4-year mark. For individuals with 3+ events, the 1-year AUC is higher (0.59 [0.53, 
0.64]) than that of individuals with fewer events, and the AUC increases over time elapsed up to 
year 3 (0.65 [0.58, 0.73]) after which it dips slightly (0.63 [0.52, 0.73]) at year 4. Observations 
with 4+ events have a marked increase in AUC at the 1-year mark (0.65 [0.56, 0.73]) than that of 
individuals with fewer events, and their AUC rises steadily over time, peaking at the 4-year mark 
(0.71 [0.57, 0.85]). Overall, these results suggest that the number and type of events in an 
individual’s clinical history is predictive of future event occurrence.  
The IHCM results are similar, and slightly improved from that of the BM. A key feature is 
the predictive role of the treatment arms at baseline (0 events); at the 1-year mark, there is a 
small but statistically significant rise in AUC (0.52 [0.51, 0.54]) which stems from the amlodipine 
arm having an increased hazard of HF over both the chlorthalidone and lisinopril arms. This effect 
of amlodipine appears to dissipate over time, as the AUC dips down to 0.50 by the 3-year mark 
(0.50 [0.49, 0.51]) and is no longer significant. The remaining results mirror that of the BM, with 
the highest AUC in individuals with 4+ events (0.66 [0.57, 0.74]) that increases to 0.71 (0.59, 0.83) 
by the 3-year time point.  
The IRHCM is similar to the IHCM, with a slightly increased AUC of individuals with 2+ 
events starting at 1 year, and individuals with 3+ events at the 2-year mark, when compared to 
the IHCM. This most likely reflects the treatment arms effects on recurrent events. For the 
individuals with 4+ events, the AUC for the IRHCM is slightly lower than that of both the IHCM 




accrued from events as they occur play a major role in dynamic risk, and the treatment arm plays 
a relatively minor role in prediction of future event occurrence and recurrence. 
6.  Discussion 
 
In this work, we presented a multi-type recurrent events model with dependent termination in a 
competing risk framework that provides a dynamic risk trajectory over time. Our model is well 
suited for longitudinal studies, which often feature recurrent events. The model provides the 
baseline hazard, or absolute risk, for each competing event type at any desired time point and 
incorporates the previous types and numbers of events in that individual in doing so. This allows 
a straightforward quantification of the relationship, if any, between different event types; the 
recurrent event parameters represent the additional hazard that a preceding nonfatal event 
confers to the event of interest. If this hazard is zero, it suggests a lack of association, or 
correlation, between those event types. 
 Our simulation study, patterned after the IRHCM, introduced covariates to the intrinsic 
hazards and the recurrent hazards. The simulation showed that our model can handle covariates 
for both the intrinsic and recurrent parameters, which results in a fairly large number of 
parameters, with relative ease. This has the potential to yield unique and important insights. Our 
work was motivated by the ALLHAT study, and our model was developed in the setting of multi-
type recurrent events in CVD that are associated with one another based on the known 
pathophysiology of CVD. Our model, when applied to the in-trial ALLHAT study, yielded results 
consistent with the main ALLHAT findings, particularly the increased intrinsic hazard for nonfatal 
HF in the amlodipine arm over that of both the chlorthalidone and lisinopril arms, and the 




Additionally, the IRHCM yielded new insights from the ALLHAT study in terms of treatment arm 
effects on recurrent events. In particular, the lisinopril arm had a lower hazard of HF conferred 
by a preceding HF compared to the chlorthalidone arm. This suggests that individuals with known 
HF may receive a benefit from lisinopril over chlorthalidone in preventing future HF events. ACE 
inhibitors are a first line agent for HF management, partly because they have been shown to 
reduce hospitalizations for recurrent HF21 and our results provide further support for the role of 
ACE inhibitors in reducing recurrent HF risk.  
A unique aspect of our method is that it provides a dynamic risk trajectory for an 
individual based on their event history, and that risk is updated with each event as it occurs. This 
can yield potent predictive capabilities for future events and can direct optimal strategies for 
event-free survival tailored to that individual’s clinical profile. We have already demonstrated 
that our models have good predictive ability for event-free survival for individuals with 4+ events 
from the 3-year mark onward, and reasonable prediction of event-free survival for individuals 
with 3+ events from the 3-year mark onward. In that regard, the BM is surprisingly competitive 
with both the IHCM and the IRHCM in terms of its ability to predictive future event occurrence 
over time. There was little difference in predictive ability between the models, which suggests 
that the hazards accrued over time by events as they occur play the dominant role in predicting 
event-free survival. This underscores a central tenet of our methodology, which is that 
accumulated events impart hazards that are cumulative, updated with each event occurrence 
over time. Moreover, we applied our model to the full in-trial ALLHAT dataset with no missing 




We acknowledge two limitations. First, the three models we applied to the ALLHAT data 
take between 5-10 minutes to converge, which is a reasonable time frame. For our simulation 
study, we deliberately chose to simulate each dataset (𝑁 = 30,000) to approximate the size of 
ALLHAT, so the 500 simulation runs took several days to complete. This can be addressed by 
simulating smaller datasets and/or fewer simulation runs, or the use of a supercomputer. A 
second limitation of our study is the somewhat large proportion of right censored observations 
for the individuals with 1+, 2+, 3+ and 4+ events starting at the 3-year mark. The handling of 
censored observations is a ubiquitous problem in survival analysis with manifold approaches. We 
elected to address it via random sampling from our model’s predicted survival probability. 
Alternative approaches to censored observations in this setting would be an interesting and 
worthwhile future research endeavor.  
Lastly, we anticipate a marked enhancement of our model’s dynamic risk prediction 
capabilities with the incorporation of additional suitable covariates into both the intrinsic hazards 
and recurrent hazards. This will involve tailored model building and selection involving a 
potentially large number of parameters. We also wish to explore possible treatment arm 
differences for specific subgroups including age, gender and race which involve interaction terms 
as covariates in our models.  We will address these important queries in our next paper, which 
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Table 1. Simulation study. 
 Parameter Truth Estimate Bias SE SD CP 
MI 𝝁𝑴       
 C 0.0109 0.0110 0.0001 0.0004 0.0004 0.954 
 A -0.0005 -0.0005 <0.0001 0.0006 0.0006 0.952 
 L -0.0007 -0.0008 -0.0001 0.0006 0.0006 0.952 
 𝜷𝑴𝑴       
 C 0.0588 0.0590 0.0002 0.0053 0.0051 0.954 
 A -0.0056 -0.0059 -0.0003 0.0074 0.0074 0.950 
 L -0.0055 -0.0060 -0.0005 0.0075 0.0071 0.958 
 𝜷𝑴𝑺       
 C 0.0135 0.0138 0.0003 0.0046 0.0047 0.932 
 A 0.0019 0.0021 0.0002 0.0068 0.0068 0.944 
 L -0.0043 -0.0047 -0.0004 0.0060 0.0061 0.954 
 𝜷𝑴𝑯       
 C 0.0123 0.0122 -0.0001 0.0039 0.0040 0.946 
 A 0.0075 0.0078 0.0003 0.0055 0.0053 0.960 
 L 0.0027 0.0029 0.0002 0.0057 0.0055 0.960 
        
Stroke 𝝁𝑺       
 C 0.0063 0.0063 <0.0001 0.0003 0.0003 0.944 
 A -0.0006 -0.0006 <0.0001 0.0005 0.0005 0.950 
 L 0.0007 0.0007 <0.0001 0.0005 0.0005 0.926 
 𝜷𝑺𝑴       
 C 0.0013 0.0013 <0.0001 0.0016 0.0018 0.930 
 A 0.0011 0.0010 -0.0001 0.0025 0.0025 0.956 
 L 0.0097 0.0098 0.0001 0.0032 0.0033 0.950 
 𝜷𝑺𝑺       
 C 0.0248 0.0248 <0.0001 0.0050 0.0048 0.958 
 A 0.0022 0.0023 0.0001 0.0074 0.0074 0.940 
 L -0.0020 -0.0018 0.0002 0.0069 0.0070 0.946 
 𝜷𝑺𝑯       
 C 0.0031 0.0033 0.0002 0.0022 0.0025 0.918 
 A 0.0061 0.0058 -0.0003 0.0034 0.0035 0.930 
 L -0.0008 -0.0012 -0.0004 0.0032 0.0036 0.912 
        
HF 𝝁𝑯       
 C 0.0056 0.0055 -0.0001 0.0003 0.0003 0.936 
 A 0.0029 0.0029 <0.0001 0.0005 0.0005 0.960 
 L 0.0008 0.0008 <0.0001 0.0005 0.0005 0.958 
 𝜷𝑯𝑴       
 C 0.0522 0.0518 -0.0004 0.0050 0.0051 0.938 




 L 0.0079 0.0082 0.0003 0.0076 0.0073 0.966 
 𝜷𝑯𝑺       
 C 0.0175 0.0176 0.0001 0.0046 0.0048 0.932 
 A -0.0082 -0.0081 0.0001 0.0062 0.0063 0.960 
 L -0.0019 -0.0019 <0.0001 0.0062 0.0064 0.940 
 𝜷𝑯𝑯       
 C 0.1431 0.1435 0.0004 0.0100 0.0097 0.958 
 A -0.0213 -0.0217 -0.0004 0.0127 0.0123 0.952 
 L -0.0337 -0.0346 -0.0009 0.0132 0.0130 0.952 
        
Death 𝝁𝑫       
 C 0.0279 0.0279 <0.0001 0.0007 0.0007 0.958 
 A -0.0015 -0.0016 -0.0001 0.0010 0.0010 0.966 
 L -0.0008 -0.0008 <0.0001 0.0010 0.0010 0.948 
 𝜷𝑫𝑴       
 C 0.0163 0.0167 0.0004 0.0042 0.0043 0.942 
 A -0.0029 -0.0033 -0.0004 0.0059 0.0062 0.944 
 L -0.0039 -0.0042 -0.0003 0.0060 0.0061 0.956 
 𝜷𝑫𝑺       
 C 0.0540 0.0541 0.0001 0.0084 0.0084 0.962 
 A -0.0017 -0.0012 0.0005 0.0119 0.0121 0.956 
 L -0.0011 -0.0008 0.0003 0.0114 0.0115 0.952 
 𝜷𝑫𝑯       
 C 0.0752 0.0754 0.0002 0.0080 0.0080 0.932 
 A -0.0096 -0.0095 0.0001 0.0102 0.0103 0.944 
 L 0.0039 0.0040 0.0001 0.0112 0.0109 0.954 
SE, standard error; SD, standard deviation; CP, coverage probability; C, chlorthalidone; A, 






Table 2. Base (intercept only) model.  
  
 Parameter Estimate (95% CI) 
MI 𝝁𝑴 0.0106 (0.0101, 0.0111) 
 𝜷𝑴𝑴 0.0559 (0.0492, 0.0627) 
 𝜷𝑴𝑺 0.0127 (0.0070, 0.0183) 
 𝜷𝑴𝑯 0.0154 (0.0102, 0.0206) 
   
Stroke 𝝁𝑺 0.0063 (0.0059, 0.0067) 
 𝜷𝑺𝑴 0.0038 (0.0014, 0.0063) 
 𝜷𝑺𝑺 0.0249 (0.0186, 0.0312) 
 𝜷𝑺𝑯 0.0049 (0.0018, 0.0080) 
   
HF 𝝁𝑯 0.0066 (0.0062, 0.0070) 
 𝜷𝑯𝑴 0.0584 (0.0514, 0.0654) 
 𝜷𝑯𝑺 0.0150 (0.0094, 0.0205) 
 𝜷𝑯𝑯 0.1270 (0.1155, 0.1384) 
   
Death 𝝁𝑫 0.0273 (0.0264, 0.0281) 
 𝜷𝑫𝑴 0.0146 (0.0092, 0.0199) 
 𝜷𝑫𝑺 0.0533 (0.0430, 0.0635) 







Table 3. Intrinsic hazards covariate model. 
 
  Baseline hazard Excess hazard 
   Reference Group: 
Chlorthalidone 
(A vs C and L vs C) 
Reference Group: 
Lisinopril 
(A vs L) 
 Parameter Estimate (95% CI) Estimate (95% CI) Estimate (95% CI) 
MI 𝝁𝑴    
 C 0.0109 (0.0102, 0.0117)  -- 
 A 0.0105 (0.0096, 0.0115) -0.0004 (-0.0017, 0.0008) 0.0003 (-0.0010, 0.0017) 
 L 0.0102 (0.0092, 0.0111) -0.0008 (-0.0020, 0.0005)  
     
 𝜷𝑴𝑴 0.0559 (0.0492, 0.0626)   
 𝜷𝑴𝑺 0.0127 (0.0070, 0.0183)   
 𝜷𝑴𝑯 0.0155 (0.0103, 0.0206)   
     
Stroke 𝝁𝑺    
 C 0.0062 (0.0056, 0.0068)  -- 
 A 0.0057 (0.0050, 0.0065) -0.0005 (-0.0014, 0.0004) -0.0014 (-0.0024, -0.0003)* 
 L 0.0071 (0.0063, 0.0079) 0.0009 (-0.0001, 0.0019)  
     
 𝜷𝑺𝑴 0.0037 (0.0012, 0.0062)   
 𝜷𝑺𝑺 0.0249 (0.0186, 0.0312)   
 𝜷𝑺𝑯 0.0050 (0.0019, 0.0081)   
     
HF 𝝁𝑯    
 C 0.0056 (0.0050, 0.0061)  -- 
 A 0.0085 (0.0076, 0.0093) 0.0029 (0.0019, 0.0039)* 0.0021 (0.0009, 0.0033)* 
 L 0.0064 (0.0056, 0.0071) 0.0008 (-0.0001, 0.0017)  
     




 𝜷𝑯𝑺 0.0152 (0.0096, 0.0207)   
 𝜷𝑯𝑯 0.1269 (0.1154, 0.1383)   
     
Death 𝝁𝑫    
 C 0.0279 (0.0267, 0.0291)  -- 
 A 0.0263 (0.0248, 0.0278) -0.0016 (-0.0036, 0.0003) -0.0008 (-0.0030, 0.0014) 
 L 0.0271 (0.0255, 0.0287) -0.0008 (-0.0028, 0.0011)  
 𝜷𝑫𝑴 0.0145 (0.0091, 0.0199)   
 𝜷𝑫𝑺 0.0533 (0.0430, 0.0635)   
 𝜷𝑫𝑯 0.0731 (0.0635, 0.0826)   
*statistically significant excess hazard over that of the reference group 
C, the baseline hazard for chlorthalidone (left column); A, the baseline hazard for amlodipine (left column), the excess hazard over 
chlorthalidone for amlodipine (middle column) and excess hazard over lisinopril for amlodipine (right column); L, the baseline hazard 






Table 4. Intrinsic and recurrent hazards covariate model. 
  Baseline hazard Excess hazard 
   Reference Group: 
Chlorthalidone 
(A vs C and L vs C) 
Reference Group: 
Lisinopril 
(A vs L) 
 Parameter Estimate (95% CI) Estimate (95% CI) Estimate (95% CI) 
MI 𝝁𝑴    
 C  0.0109 (0.0102, 0.0117)  -- 
 A 0.0105 (0.0095, 0.0115) -0.0005 (-0.0017, 0.0008) 0.0003 (-0.0011, 0.0016) 
 L 0.0102 (0.0093, 0.0112) -0.0007 (-0.0020, 0.0005)  
 𝜷𝑴𝑴    
 C  0.0588 (0.0489, 0.0688)  -- 
 A 0.0532 (0.0403, 0.0661) -0.0056 (-0.0219, 0.0107) -0.0001 (-0.0183, 0.0182) 
 L 0.0533 (0.0403, 0.0663) -0.0055 (-0.0219, 0.0108)  
 𝜷𝑴𝑺    
 C  0.0135 (0.0050, 0.0220)    -- 
 A 0.0154 (0.0033, 0.0275)  0.0019 (-0.0129, 0.0167) 0.0062 (-0.0091, 0.0215) 
 L 0.0092 (-0.0002, 0.0186) -0.0043 (-0.0170, 0.0083)    
 𝜷𝑴𝑯    
 C  0.0123 (0.0047, 0.0199)    -- 
 A 0.0198 (0.0099, 0.0297)  0.0075 (-0.0049, 0.0200)   0.0049 (-0.0089, 0.0186) 
 L 0.0149 (0.0053, 0.0246)  0.0027 (-0.0096, 0.0149)  
     
Stroke 𝝁𝑺    
 C  0.0063 (0.0057, 0.0069)  -- 
 A 0.0057 (0.0050, 0.0064) -0.0006 (-0.0015, 0.0003)   -0.0013 (-0.0024, -0.0002)* 
 L 0.0070 (0.0062, 0.0078)  0.0007 (-0.0003, 0.0017)    
 𝜷𝑺𝑴    
 C  0.0013 (-0.0016, 0.0042)    -- 




 L 0.0110 (0.0042, 0.0177)    0.0097 (0.0023, 0.0170)*  
 𝜷𝑺𝑺    
 C  0.0248 (0.0154, 0.0342)    -- 
 A 0.0270 (0.0140, 0.0401)  0.0022 (-0.0139, 0.0183) 0.0042 (-0.0130, 0.0213) 
 L 0.0228 (0.0117, 0.0339) -0.0020 (-0.0165, 0.0126)    
 𝜷𝑺𝑯    
 C  0.0031 (-0.0015, 0.0077)    -- 
 A 0.0093 (0.0028, 0.0157)  0.0061 (-0.0018, 0.0141) 0.0069 (-0.0011, 0.0150) 
 L 0.0023 (-0.0025, 0.0072) -0.0008 (-0.0075, 0.0059)  
     
HF 𝝁𝑯    
 C 0.0056 (0.0050, 0.0061)  -- 
 A 0.0085 (0.0076, 0.0093)    0.0029 (0.0019, 0.0040)*   0.0021 (0.0009, 0.0033)* 
 L 0.0064 (0.0056, 0.0071)  0.0008 (-0.0001, 0.0018)    
 𝜷𝑯𝑴    
 C  0.0522 (0.0427, 0.0617)    -- 
 A 0.0683 (0.0533, 0.0833)  0.0161 (-0.0016, 0.0338)   0.0082 (-0.0121, 0.0285) 
 L 0.0601 (0.0463, 0.0739)  0.0079 (-0.0089, 0.0246)  
 𝜷𝑯𝑺    
 C  0.0175 (0.0089, 0.0261)  -- 
 A 0.0094 (-0.0010, 0.0198) -0.0082 (-0.0217, 0.0053) -0.0062 (-0.0206, 0.0081) 
 L 0.0156 (0.0057, 0.0255) -0.0019 (-0.0150, 0.0112)     
 𝜷𝑯𝑯    
 C  0.1431 (0.1239, 0.1623)  -- 
 A 0.1218 (0.1019, 0.1418) -0.0213 (-0.0490, 0.0064) 0.0124 (-0.0158, 0.0406) 
 L 0.1094 (0.0894, 0.1294)    -0.0337 (-0.0614, -0.0059)*  
     
Death 𝝁𝑫    
 C  0.0279 (0.0266, 0.0291)  -- 
 A 0.0264 (0.0248, 0.0279) -0.0015 (-0.0035, 0.0005) -0.0007 (-0.0029, 0.0015) 




 𝜷𝑫𝑴    
 C  0.0163 (0.0082, 0.0244)  -- 
 A 0.0134 (0.0036, 0.0231) -0.0029 (-0.0156, 0.0098) 0.0010 (-0.0133, 0.0153) 
 L 0.0124 (0.0019, 0.0228) -0.0039 (-0.0172, 0.0093)  
 𝜷𝑫𝑺    
 C  0.0540 (0.0386, 0.0695)  -- 
 A 0.0524 (0.0318, 0.0729) -0.0017 (-0.0274, 0.0240) -0.0006 (-0.0282, 0.0269) 
 L 0.0530 (0.0346, 0.0714) -0.0011 (-0.0251, 0.0229)    
 𝜷𝑫𝑯    
 C  0.0752 (0.0596, 0.0907)  -- 
 A 0.0655 (0.0496, 0.0815) -0.0096 (-0.0319, 0.0127)   -0.0135 (-0.0380, 0.0110) 
 L 0.0790 (0.0605, 0.0976)  0.0039 (-0.0203, 0.0281)  
*statistically significant excess hazard over that of the reference group 
C, the baseline hazard for the corresponding category (intrinsic, recurrent) for chlorthalidone (left column); A, the baseline hazard for 
the corresponding category (intrinsic, recurrent) for amlodipine (left column), the excess hazard over chlorthalidone for the 
corresponding category (intrinsic, recurrent) for amlodipine (middle column) and the excess hazard over lisinopril for the 
corresponding category (intrinsic, recurrent) for amlodipine (right column); L, the baseline hazard for the corresponding category 




Table 5. Model AIC. 
 BM IHCM IRHCM 
Number of 
parameters 
16 24 48 







Table 6. Number and percentage of censored observations. 










 n (%) n (%) n (%) n (%) n (%) 
1 111 (0.33) 385 (10.60) 126 (12.41) 52 (13.27) 24 (15.48) 
2 141 (0.42) 845 (23.27) 229 (22.56) 87 (22.19) 32 (20.65) 
3 206 (0.62) 1241 (34.18) 331 (32.61) 120 (30.61) 37 (23.87) 







Table 7. Area under the curve for the BM. 
Year 0 events 1+ events 2+ events 3+ events 4+ events 
 N=33,357 N=3,631 N=1,015 N=392 N=155 
1 0.50 






(0.53, 0.64)  
0.65 
(0.56, 0.73) 
2 0.50  



















4 0.50  















Table 8. Area under the curve for the IHCM. 
Year 0 events 1+ events 2+ events 3+ events 4+ events 








(0.53, 0.64)  
0.66 
(0.57, 0.74) 




































Table 9. Area under the curve for the IRHCM. 
Year 0 events 1+ events 2+ events 3+ events 4+ events 








(0.54, 0.65)  
0.63 
(0.54, 0.72) 












































CHAPTER 3: JOURNAL ARTICLE 2 
Competing risks of recurrent cardiovascular events with all-cause mortality 
ABSTRACT 
Despite a number of established risk scores for cardiovascular disease (CVD), none to date 
provide a risk assessment of multiple, competing CVD outcomes that incorporates number and 
type of CVD events along with clinical profile. We extend our previously reported multi-type 
recurrent events model to develop several models (IHCM 1, IHCM 2 and IRHCM) that were 
applied to the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial 
(ALLHAT) study. IHCM 1 and IRHCM quantified the dynamic risks of nonfatal myocardial infarction 
(MI), stroke and heart failure (HF), and all-cause mortality (death) given risk factors for each 
event-type, with risks updated after every event occurrence. IHCM2 examined interactions 
between selected CVD risk factors and treatment arms. Baseline age, diabetes, history of MI or 
stroke, kidney disease and smoking are risk factors common to all 4 event-types. Diabetes and 
kidney disease each impart more risk to death than nonfatal events. Atrial fibrillation confers 
more risk to HF than it does to death or stroke. IHCM 2 showed significant interactions between 
diabetes and amlodipine for HF; black race and lisinopril for stroke; atrial fibrillation and 
amlodipine and lisinopril for death. IRHCM outperformed IHCM 1 in predicting event-free 
survival, and both models performed best at baseline (0 events) and in individuals with 4+ events. 
IHCM 1 and IRHCM are useful in identifying and quantifying risk factors for CVD and predicting 
risk trajectory and event-free survival, with significant potential to develop into a dynamic CVD 
risk score that guides individualized therapeutic management.   





Major risk factors for cardiovascular disease (CVD) are well established.1-3 The 
Framingham risk score is widely used in clinical practice and epidemiological research 2,4; it was 
originally developed to calculate 10-year risks of coronary heart disease (CHD) utilizing several of 
these established risk factors: age, dyslipidemia, blood pressure, diabetes, and smoking.2,4 
Subsequently, cerebrovascular events, peripheral artery disease (PAD) and heart failure (HF) 
were added to formulate a more general CVD risk assessment tool, expanding the Framingham 
risk score to include 10-year risks of CVD 2,5.  
 In spite of the ubiquitous use of risk scores to predict CVD outcomes and preferentially 
target individuals at particular risk of CVD events in the short and long term, there has not been 
to our knowledge a risk score or risk assessment of CVD outcomes that incorporate specific 
number and types of CVD events in an individual’s past medical history in conjunction with their 
clinical and demographic profile. In our previous work, 6 we introduced a dynamic competing risk 
model for multi-type recurrent events that is uniquely tailored to quantify baseline hazard, or 
absolute risk, of future CVD events given the individual’s particular event history e.g. a personal 
history of nonfatal myocardial infarction (MI), stroke and 2 episodes of HF. Recurrent CVD events 
are a common feature of longitudinal studies, and it is known that each CVD event imparts risk 
for future CVD events.1 Therefore, the gap time, or time between CVD events or between a CVD 
event and death tends to decrease, particularly in the absence of intervention. Our model 
hypothesizes that each nonfatal CVD event imparts a particular risk to the future occurrence of 
each type of nonfatal CVD event (including its own recurrence) and a different, also particular, 




risk as well as a dependent terminal event after which no further events can occur. Moreover, 
our model assumes that the risk imparted by a particular CVD event on another CVD outcome is 
explained by a unique set of covariates, possibly time-dependent.  
 This approach yields valuable clinical insights to the nature of CVD and CVD mortality and 
the particular risk factors that are most relevant in preventing or ameliorating first occurrence of 
a CVD event, future occurrence or recurrence of CVD events, and death. Our model would show 
that certain risk factors such as diabetes, renal insufficiency and atrial fibrillation may pose 
greater risks to certain CVD events over others. Furthermore, head to head comparisons between 
drug regimens and other medical therapeutic interventions in their ability to thwart the incidence 
and recurrence of CVD and CVD-related death can be made. The global disease burden of CVD is 
enormous and cannot be overstated.7 CVD is the leading cause of death worldwide and its 
chronic, recurrent nature and often devastating consequences including lifelong disability and 
death make such a detailed CVD risk assessment as provided by our model an urgent clinical and 
public health imperative.1,7 
 Our recurrent events statistical model described in our previous paper 6 was motivated 
by the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) 
study. In this paper, we return to the ALLHAT dataset to extend our methodology to include 
relevant clinical covariates for the intrinsic hazard every individual has for CVD events and death. 
We will further extend our method to select appropriate covariates for recurrent hazards, i.e. the 
hazard imparted by a CVD event for future CVD events. These two aforementioned models are 
extensions of the intrinsic hazards covariate model (IHCM) and intrinsic and recurrent hazards 




clinically important variables and treatment arms will be explored as another variant of the IHCM 




ALLHAT’s study population has been described elsewhere.8,9 Briefly, ALLHAT was a 
double-blind, randomized controlled trial that was conducted from February 1994 through 
March 2002. Participants were aged 55 or older with hypertension and at least one additional 
CVD risk factor [including previous (> 6 months) MI or stroke, left ventricular hypertrophy (LVH), 
history of Type 2 diabetes (hereafter, diabetes), current cigarette smoking, high-density 
lipoprotein (HDL) < 35 mg/dl, or documentation of other atherosclerotic CVD (OASCVD)] from 
623 centers in North America, specifically the United States, Canada, Puerto Rico and the US 
Virgin Islands. A total of 33,357 individuals were randomized to one of three treatment arms: 
chlorthalidone (𝑁 = 15,255), amlodipine (𝑁 = 9,048) and lisinopril (𝑁 = 9,054) for planned 
follow-up of approximately 4 to 8 years. Mean follow-up time was 4.9 years. The primary 
endpoint was fatal CHD or nonfatal MI. Major pre-specified secondary outcomes were all-cause 
mortality, fatal and nonfatal stroke, combined CHD (the primary outcome, coronary 
revascularization, and hospitalized angina), and combined CVD [combined CHD, stroke, other 
treated angina, HF (fatal, hospitalized, or treated non-hospitalized) and PAD]. ALLHAT was 
designed to determine whether the occurrence of fatal CHD or nonfatal MI (the primary 




(amlodipine) or an ACE inhibitor (lisinopril), each compared to diuretic treatment 
(chlorthalidone).8,9 
Statistical model 
Since our model has been described at length in our previous work, 6 we will quickly 
recapitulate its salient aspects here before we proceed to describe the IHCM and IRHCM models 
that comprise the bulk of our statistical analyses. We let 𝛼𝑀, 𝛼𝑆, 𝛼𝐻 and 𝛼𝐷 denote the hazards 
(risks) for nonfatal MI, nonfatal stroke, nonfatal HF, and death from any cause (hereafter referred 
to as death), respectively. From this juncture, MI, stroke and HF will be assumed nonfatal unless 
otherwise noted. Each of the hazards 𝛼𝑀, 𝛼𝑆, 𝛼𝐻 and 𝛼𝐷 are assumed to be dependent on that 
individual’s event history. We further assume that there is an intrinsic hazard for each event (MI, 
stroke, HF and death). Each nonfatal event then imposes an additional hazard to itself (its own 
recurrence) and an additional, different hazard to each of the other two nonfatal events and 
death. Death, being the terminal event, has its own intrinsic hazard plus additional hazards 
accrued from any nonfatal events (MI, stroke, HF) that have occurred up to the point of interest. 
Throughout this paper, we will use the terms hazard, risk and absolute risk interchangeably. 
Our model therefore updates the hazards 𝛼𝑀 , 𝛼𝑆, 𝛼𝐻 , and 𝛼𝐷 dynamically as nonfatal 



























































where 𝑚𝑖𝑗, 𝑛𝑖𝑗, and  𝑝𝑖𝑗 represent the total number of MI’s, strokes and HF’s, respectively that 
have occurred prior to event time 𝑡𝑖𝑗; 𝑡𝑖𝑗 denotes the time of the 𝑗
𝑡ℎ event in the 𝑖𝑡ℎ individual. 
Our model delineates two main types of hazards: intrinsic and event-type. The intrinsic hazards 
for MI, stroke, HF and death are expressed by regression covariate coefficient vectors 𝝁𝑴, 𝝁𝑺, 𝝁𝑯 
and 𝝁𝑫 associated with covariate vectors 𝑿𝑴𝒊(𝑡), 𝑿𝑺𝒊(𝑡), 𝑿𝑯𝒊(𝑡) and 𝑿𝑫𝒊(𝑡), respectively. These 
intrinsic hazards are the underlying hazards every individual has for those events. The recurrent 
parameters denoted by regression covariate coefficient vectors 𝜷𝑴𝑴, … , 𝜷𝑫𝑯 and associated 
with covariate vectors 𝑿𝑴𝑴𝒊(𝑡), … , 𝑿𝑫𝑯𝒊(𝑡) represent the event-type hazards, i.e. the additional 
hazard for a particular event, nonfatal or fatal, conferred by a particular preceding nonfatal 
event. Thus, 𝑿′• 𝑴𝒊(𝑡)𝜷• 𝑴 is the additional hazard for any event type (MI, stroke, HF or death) 




is the additional hazard for any event type (MI, stroke, HF or death) conferred by preceding stroke 
specifically in the 𝑖th individual with covariates 𝑿• 𝑺𝒊(𝑡), and so on. The covariate vectors are 
unique to each hazard type and may be time dependent. 
Thus, each hazard can be characterized by a unique, possibly time dependent, set of 
covariates which results in each individual having a tailored hazard for every CVD event and 
death, at baseline. These hazards update dynamically as the person moves through time and 
possibly accrues further CVD events. The IHCM and IRHCM are two models that arise naturally 
from the above rationale. For the IHCM, the intrinsic hazards contain covariates whereas the 
recurrent hazards do not contain covariates, i.e. they are left as intercepts. For the IRHCM, both 
the intrinsic and recurrent hazards may contain covariates. For IHCM and IRHCM and the 




equivalent to the annual incidence of MI, stroke, HF and death. All of our statistical analyses were 
carried out in R 3.4.4 (R Foundation for Statistical Computing, Vienna, Austria); parameter 
estimations were carried out by a modified Newton-Raphson algorithm described in our previous 
work 6 and independently verified by R’s optim function (provided in the base package) using the 
BFGS algorithm.  
Statistical analyses 
 The ICHM is the more parsimonious model and we report two separate sub-analyses of 
epidemiological and clinical significance. We denote the first as IHCM 1, for which we performed 
a modified stepwise variable selection to determine the most important covariates that comprise 
the intrinsic hazards for MI, stroke, HF and death.  
 We began with the full IHCM 1, comprised of the covariates deemed most important for 
CVD. We included key baseline characteristics of the ALLHAT participants that are known to be 
associated with CVD: age, race, sex, whether or not hypertension was treated at baseline, stage 
1 or stage 2 hypertension as determined from baseline systolic and diastolic blood pressure, 
smoking, previous MI or stroke, history of coronary revascularization (CABG), OASCVD, major ST 
depression or T wave inversion, diabetes, left ventricular hypertrophy (LVH) by echocardiogram, 
CHD, body mass index (BMI) and current aspirin use. For this paper, we used the previous 
definition of stage 1 hypertension [systolic blood pressure (SBP) 140-160 mm Hg or diastolic 
blood pressure (DBP) 90-100 mm Hg] and stage 2 hypertension [SBP > 160 mm Hg or DBP > 100 
mm Hg] 10 to better reflect the ALLHAT in-trial period. Additionally, we added covariates that are 
known CVD risk factors 1: baseline or incident atrial fibrillation (hereafter, atrial fibrillation) and 




Lastly, we included the treatment arms amlodipine and lisinopril, with chlorthalidone serving as 
the reference group for a total of 19 covariates for each intrinsic hazard (MI, stroke, HF and 
death). Notably, we deliberately excluded HDL < 35 mg/dL, one of the ALLHAT baseline 
characteristics reported in the literature 8,9 as a covariate for two main reasons. First and 
foremost, a subset of the ALLHAT participants were enrolled during the trial into the Lipid-Lowing 
Trial (ALLHAT-LLT) and were randomly assigned to receive pravastatin vs usual care and followed 
for a mean of 4.8 years.11 This naturally introduces potential confounding as to the true effect of 
dyslipidemia as measured by baseline HDL < 35 mg/dL on CVD events over the course of the trial. 
Secondly, we ran a univariate IHCM with HDL < 35 mg/dL as the only covariate for all of the 
intrinsic hazards with equivocal results: HDL < 35 mg/dL was not found to impart a statistically 
significant hazard for MI or HF, and actually found to impart a statistically significant decrease in 
hazard for stroke and death. These results are consistent with a potentially confounding effect 
from the ALLHAT-LLT participants in the course of the ALLHAT study. Moreover, we ran a 
univariate IHCM for each of the 19 covariates included in the full IHCM to determine its univariate 
statistical significance as part of our model building and stepwise selection process (univariate 
IHCM results not shown). Table 1 lists the details for the 19 covariates included in the full IHCM 
1.  
 Starting with the full IHCM 1, we performed multiple rounds of backward selection. In 
each round, we only retained the statistically significant covariates, i.e. the covariates which 
imparted a statistically significant hazard to the total intrinsic hazards for MI, stroke, HF and 
death, with one important constraint: we retained the treatment arms (amlodipine and lisinopril, 




significance throughout in order to adjust for treatment arm. In the first round of background 
selection only the statistically significant covariates for each intrinsic hazard were retained, and 
a reduced IHCM 1 model was fitted with these statistically significant covariates from the first 
round. In this reduced IHCM 1 model (second round), any covariates that were no longer 
statistically significant were discarded, and so on. The final reduced IHCM 1 contained only those 
covariates that remained statistically significant in each round of backward selection, with the 
noted exception of the treatment arms. We also removed a covariate even if it remained 
statistically significant for a particular intrinsic hazard or set of intrinsic hazards, if it was not 
statistically significant in the initial set of univariate analyses that we carried out for every 
covariate in the full IHCM 1 model. And finally, ALLHAT’s population, given that every participant 
had a diagnosis of hypertension and 1 or more additional CVD risk factors at baseline, posed a 
unique challenge for variable selection; all statistically significant risk factors (covariates) could 
not be included for stroke, HF and death as it would result in the reference group being too sparse 
(the reference group being comprised of individuals without any of those risk factors). Therefore, 
we had to remove additional covariates that remained statistically significant for stroke, HF and 
death for optimal model stability to avoid the problems that arise with sparse data. Table 2 
reports the covariates removed during multiple rounds of backward selection to yield the final 
IHCM 1 model (henceforth, IHCM 1). 
 In order to study the possible interactions between treatment arms and selected risk 
factors, we utilized IHCM 2, which contains as its covariates: the risk factor (binary or categorical), 
amlodipine, lisinopril and the interaction terms [(risk factor) x (treatment arm)]. The selected risk 




atrial fibrillation, hypertension treated at baseline and stage 1/stage 2 hypertension at baseline 
(categorical, see Table 1). Of note, interactions for age, sex, race (black/nonblack) and diabetes 
were previously studied in ALLHAT 8; we wanted to reexamine those interactions in a competing 
risk framework for nonfatal CVD events and death with IHCM 2, and also examine additional risk 
factors that play a crucial role in CVD: kidney disease, atrial fibrillation and hypertension. The 
same set of covariates is included for each of the four intrinsic hazards (MI, stroke, HF and death) 
for every interaction model with the recurrent hazards left as intercepts.   
 For the IRHCM, we began with IHCM 1 and added the full set of covariates (see Table 1) 
for each recurrent hazard and performed multiple rounds of backward selection to determine 
which covariates retained statistical significance for that recurrent hazard. Thus, we began with 
the full covariates for 𝜷𝑴𝑴 (corresponding to covariate vector 𝑿𝑴𝑴𝒊) and determined its final set 
of covariates via rounds of backward of selection. We then proceeded to perform variable 
selection for 𝜷𝑴𝑺 in the same manner, retaining the final set of variables for the preceding 𝜷𝑴𝑴, 
and so on, until variable selection for the last regression covariate coefficient vector, 𝜷𝑫𝑯 was 
completed. Throughout this variable selection process, we assessed the goodness of fit for the 
model up to that point using the approach that we described previously.6 Very briefly, we 
predicted event-free survival at 1-year, 2-year, 3-year and 4-year increments for all individuals at 
baseline, individuals that had 1 or more events, individuals that had 2 or more events, individuals 
that had 3 or more events and individuals that had 4 or more events. Our dataset contained the 
binary result of whether or not that individual had any event, nonfatal or fatal, within that time 
frame; censored observations were handled in a manner identical to that detailed in our previous 




resulting receiver operating characteristic (ROC) curve for each time frame and number of events, 
and this AUC was a measure of goodness of fit for the model. 
 For the IRHCM, the goodness of fit played a role in variable selection. If we found that the 
statistically significant covariates that remained after backward selection for a particular 
recurrent hazard resulted in lower AUC’s for one or more event histories (e.g. individuals with 3+ 
events, individuals with 4+ events, and so on) then we did not retain those covariates and opted 
for an intercept term for that recurrent hazard. We report the backward selection process for 
IRHCM in Table 3. 
RESULTS 
 For IHCM 1 and IRHCM, a total of 3,062 observations (9.18%) were removed from the full 
ALLHAT in-trial dataset (𝑁 = 33,357) due to missing values in the covariates, resulting in 30,295 
observations for those analyses. For IHCM 2, 1,331 observations were removed for atrial 
fibrillation due to missing covariates resulting in 32,026 observations; 1,460 observations were 
removed for kidney disease due to missing covariates resulting in 31,897 observations; 1 
observation was removed for hypertension treated at baseline due to a missing covariate 
resulting in 33,356 observations. The parameter estimates and their 95% confidence intervals 
(CI’s) for IHCM 1 are reported in Table 4. The intercept term for each intrinsic hazard regression 
covariate coefficient vector (𝝁𝑴, 𝝁𝑺, 𝝁𝑯 and 𝝁𝑫 for MI, stroke, HF and death, respectively) 
represents the reference group for all of the covariates in that intrinsic hazard. For MI, the 
intercept term for 𝝁𝑴 corresponds to the reference group for all MI covariates, i.e. individuals 
55-64 years of age, nondiabetic, no MI or stroke prior to the study, female, no prior CABG, no 




nonsmokers and in the chlorthalidone treatment arm. The MI intrinsic hazard parameter 
intercept [0.0011 (0.0001, 0.0022)] represents the annual incidence of MI in these individuals. 
The remaining parameters that comprise 𝝁𝑴 represent the additional, or excess, hazard 
contributed by that covariate (which may be positive or negative) such that the covariate may 
increase or decrease the absolute risk (in this case, annual incidence of MI). Neither amlodipine 
nor lisinopril conferred statistically significant excess risk to MI as compared to chlorthalidone. 
As an illustrative example, diabetes would impart an excess hazard of 0.0030, such that a diabetic 
individual who was in the reference category for all other covariates would have an annual 
incidence of MI: [0.0011 + 0.0030 = 0.0041]. For MI, age (the 65-79 year and 80+ year age groups), 
diabetes, prior MI or stroke, male sex, previous CABG, history of OASCVD, kidney disease (eGFR 
< 60 mL/min/1.73m2), aspirin use and smoking (past and current) are all statistically significant 
risk factors that directly contribute to the annual incidence of MI. As a further example, a 66-
year-old male diabetic with kidney disease and history of OASCVD, who is a past smoker and 
randomized to the chlorthalidone treatment arm would have an annual incidence of MI: [0.0011 
+ 0.0035 + 0.0030 + 0.0038 + 0.0020 + 0.0019 + 0.0013 = 0.0166] and 95% CI (0.0144, 0.0188). 
This corresponding Wald 95% CI is constructed using the standard error obtained from the 
informative matrix which is itself obtained in the standard manner from the hessian matrix of the 
log likelihood function detailed in our previous work 6 at the converged maximum likelihood 
estimates.  
The recurrent hazards (𝜷𝑴𝑴, 𝜷𝑴𝑺 and 𝜷𝑴𝑯) are intercept terms and they are all positive 
and statistically significant. Thus, MI, stroke and HF each imparts an additional (or excess) hazard 




to its own recurrence [𝜷𝑴𝑴; 0.0543 (0.0473, 0.0613)], HF imparts the next highest hazard to 
future MI [𝜷𝑴𝑯; 0.0123 (0.0070, 0.0175)]; followed by stroke [𝜷𝑴𝑺; 0.0092 (0.0035, 0.0149)]. The 
intrinsic hazard of MI (as well as stroke, HF and death) can be calculated for any individual in the 
dataset using a linear combination of their covariates and the parameter estimates provided in 
Table 4; furthermore, the total hazard of any event (MI, stroke, HF or death) can be calculated as 
the sum of that event’s intrinsic hazard, and any recurrent hazards accrued from prior nonfatal 
events (MI, stroke and HF) that have occurred up to that point. To extend our example from the 
previous paragraph, that very same 66-year-old male if he develops 1 MI, 0 strokes and 1 HF in 
the course of the study up to the time point of interest, his updated annual incidence of MI would 
be: [0.0166 + 0.0543 + 0 + 0.0123 = 0.0832] with 95% CI (0.0748, 0.0916). 
The full results for MI, stroke, HF and death for IHCM 1 are provided in Table 4. We will 
highlight the key results. Age, diabetes, previous MI or stroke, kidney disease and smoking are 
the common risk factors for all of the intrinsic hazards (MI, stroke, HF and death). We first note 
that age has a linear relationship with intrinsic stroke risk: from age 55 onward, the absolute risk 
of stroke [0.0023 (0.0020, 0.0026)] increases linearly with every decade. We found in our 
statistical analyses that the ordinal age variable (see Table 1 for details) provided the best fit (as 
measured by the Akaike information criterion [AIC]) for univariate and multivariate IHCM models. 
Furthermore, diabetes imparts a greater intrinsic risk to HF [0.0038 (0.0030, 0.0047)] than it does 
to MI [0.0030 (0.0019, 0.0040)] and stroke [0.0030 (0.0022, 0.0038)], respectively. Similarly, 
kidney disease imparts a greater intrinsic risk to HF [0.0037 (0.0024, 0.0050)] than it does to MI 
[0.0020 (0.0005, 0.0035)] and stroke [0.0013 (0.0002, 0.0024)]. By contrast, prior MI or stroke as 




00.0052)] and HF [0.0042 (0.0030, 0.0053)]. Atrial fibrillation imparts more risk to HF [0.0230 
(0.0174, 0.0287)] than it does to death [0.0097 (0.0038, 0.0156)] and stroke [0.0089 (0.0049, 
0.0130)], but does not pose a statistically significant risk to MI. Stage 2 hypertension at baseline 
imparts similar risk to stroke [0.0014 (0.0005, 0.0023)] and HF [0.0016 (0.0007, 0.0025)] but not 
to MI or death. Diabetes imparts a higher risk to death [0.0085 (0.0070, 0.0101)] than it does to 
the nonfatal events. Kidney disease [0.0145 (0.0119, 0.0172)] and current smoking [0.0141 
(0.0120, 0.0163)] also confer a higher risk to death than they do to the nonfatal events. Similarly, 
history of MI or stroke at baseline imparts approximately twice the risk to death [0.0088 (0.0067, 
0.0109)] that it does to nonfatal events. For the treatment arms, there is a statistically significant 
increase in risk of HF in amlodipine compared to chlorthalidone; lisinopril does not differ from 
chlorthalidone for intrinsic risk of any of the four outcomes.   
As is seen for MI, the recurrent hazards for stroke (𝜷𝑺𝑴, 𝜷𝑺𝑺 and 𝜷𝑺𝑯), HF (𝜷𝑯𝑴, 𝜷𝑯𝑺 and 
𝜷𝑯𝑯) and death (𝜷𝑫𝑴, 𝜷𝑫𝑺 and 𝜷𝑫𝑯) are all positive and statistically significant. Therefore, MI, 
stroke and HF each imparts an additional hazard for its own recurrence, and that of one another 
event’s occurrence or recurrence. Stroke imparts the greatest risk to its own recurrence [𝜷𝑺𝑺; 
0.0226 (0.0160, 0.0291)] as does HF [𝜷𝑯𝑯; 0.1230 (0.1110, 0.1350)]. HF confers the highest risk 
to death [𝜷𝑫𝑯; 0.0678 (0.0579, 0.0777)] followed by stroke [𝜷𝑫𝑺; 0.0419 (0.0315, 0.0523)] and 
then MI [𝜷𝑫𝑴; 0.0086 (0.0036, 0.0137)].  
We report the goodness of fit of IHCM 1 in Table 5. A key feature is the predictive role of 
the covariates starting from baseline (0 events); at the 1-year mark, the AUC is statistically 
significant and reasonably predictive [0.67 [0.65, 0.68]), which holds steady at 2 years [0.67 (0.66, 




(0.68, 0.69)]. However, the AUC drops for individuals with 1+ events at 1 year [0.61 (0.59, 0.63)], 
rising to [0.63 (0.61, 0.65)] at the 2-year mark, and remaining there for 3 years [0.63 (0.61, 0.65)] 
and 4 years [0.63 (0.61, 0.65)], respectively. The AUC drops further for 2+ events at 1 year [0.57 
(0.54, 0.61)] before rising slightly at the 2-year mark [0.58 (0.54, 0.62)], and continuing to rise at 
the 3-year [0.59 (0.55, 0.64)] and 4-year mark [0.62 (0.57, 0.67)], respectively. The AUC starts to 
climb back up for 3+ events at year 1 [0.60 (0.54, 0.66)], rising steadily up to year 3 [0.67 (0.59, 
0.75)] before dipping slightly at year 4 [0.65 (0.55, 0.76)]. The AUC’s are the highest overall for 
4+ events, beginning at year 1 [0.67 (0.58, 0.76)], with a steady rise at years 2 and 3 [0.68 (0.57, 
0.78) and 0.70 (0.57, 0.82), respectively] and leveling off at year 4 [0.70 (0.56, 0.84)].  
IHCM 2 examines interactions between treatment groups and the 8 selected risk factors 
described in the previous section. In Table 6, we report the results of the 3 risk factors that had 
one or more statistically significant interactions with treatment arms amlodipine and/or 
lisinopril, compared to chlorthalidone. The interaction of diabetes and amlodipine was positive 
and statistically significant for HF, which suggests that diabetes conferred a greater risk of 
developing HF in the amlodipine arm when compared to the risk of HF conferred by diabetes in 
the chlorthalidone arm. Next, the interaction of black race and lisinopril was positive and 
statistically significant for stroke. This suggests that blacks were at higher risk of stroke in the 
lisinopril group, compared to blacks’ risk of stroke in the chlorthalidone group. Finally, the 
interaction of atrial fibrillation and amlodipine, and the interaction of atrial fibrillation and 
lisinopril, are both negative and statistically significant for death compared to chlorthalidone. 
This suggests that the risk of death conferred by atrial fibrillation is lower in both amlodipine 




factors, age, sex, kidney disease, hypertension treated at baseline and stage 1/stage 2 
hypertension at baseline did not have statistically significant interactions with the treatment 
arms for MI, stroke, HF or death.  
We now turn to the IRHCM. The IRHCM retains the intrinsic hazard covariates of IHCM 1 
(Table 4) and the intrinsic hazard parameter values of IRHCM are similar or identical to that of 
IHCM 1, as expected. The recurrent hazard covariates of IRHCM, having undergone variable 
selection (modified backward selection as described in the methods section), retained several 
such covariates in the final IRHCM (Table 7). For 𝜷𝑴𝑴, which denotes the risk that MI imparts to 
its own recurrence, male sex imparts additional risk [0.0218 (0.0079, 0.0357)] to recurrent MI as 
compared to female sex; similarly, kidney disease imparts risk [0.0246 (0.0061, 0.0431)] to 
recurrent MI as compared to normal kidney function. For 𝜷𝑴𝑯, which denotes the risk that HF 
imparts to future MI, diabetes imparts additional risk [0.0136 (0.0029, 0.0242)] as compared to 
nondiabetic. For 𝜷𝑯𝑴, which denotes the risk that MI imparts to future HF occurrence, age (both 
the 65-79 years age group and the over 80+ years age group) imparts risk of [0.0182 (0.0056, 
0.0308)] and [0.0627 (0.0232, 0.1022)], respectively. Diabetes [0.0431 (0.0280, 0.0582)], history 
of OASCVD [0.0183 (0.0023, 0.0342)], and kidney disease [0.0275 (0.0081, 0.0470)] also impart 
risk to future HF occurrence in those with previous MI. Moreover, the amlodipine treatment arm 
imparts additional risk [0.0160 (0.0005, 0.0314)] compared to chlorthalidone to future HF in 
those with previous MI. For 𝜷𝑯𝑯, which denotes the risk that HF imparts to its own recurrence, 
lisinopril lowers risk [-0.0302 (-0.0553, -0.0051)] as compared to chlorthalidone for HF 
recurrence. For 𝜷𝑫𝑴, which denotes the risk that MI imparts to death, age (those 65 years and 




recurrent hazards for death; for 𝜷𝑫𝑺, age (ordinal, with the 55-64 years age group serving as the 
reference group) for every decade-increase starting at age 65 imparts risk to death from previous 
stroke [0.0228 (0.0166, 0.0290)]. For 𝜷𝑫𝑯, age 65 years and above imparts risk of death from 
prior HF. 
The goodness of fit of IRHCM is detailed in Table 8. The predictive role of the covariates 
starting at baseline (0 events) is retained and identical to that of IHCM. The AUC drops for 1+ 
events at 1 year [0.62 (0.60, 0.64)], rising to [0.64 (0.62, 0.66)] at the 2-year mark, and remaining 
there at 3 years [0.64 (0.62, 0.66)] and rising again at the 4-year point [0.66 (0.64, 0.68)]. The AUC 
drops further for 2+ events at 1 year [0.59 (0.55, 0.62)] before rising slightly at the 2-year mark 
[0.60 (0.57, 0.64)], and continuing to rise at the 3-year [0.62 (0.58, 0.66)] and 4-year mark [0.66 
(0.61, 0.70)]. The AUC starts remains lower for 3+ events at year 1 [0.59 (0.53, 0.65)], rising 
steadily up to year 3 [0.65 (0.57, 0.73)] before dipping slightly at year 4 [0.64 (0.53, 0.75)]. The 
AUC’s are highest overall for 4+ events, beginning at year 1 [0.63 (0.54, 0.72)], with a steady rise 
at years 2 and 3 [0.65 (0.54, 0.76) and 0.73 (0.60, 0.85), respectively] and jumping to [0.80 (0.67, 
0.94)] at year 4. Overall, the IRHCM AUC’s are improved over that of the IHCM, specifically for 
the 1+, 2+ and 4+ events.   
DISCUSSION 
 In this paper, we extend our previous work significantly to include important covariates 
for both the intrinsic hazards for MI, stroke, HF and death [i.e. the so-called major adverse 
cardiovascular events (MACE)] in IHCM 1, and to include important covariates for both the 




significant interest in MACE and our work provides additional, critical insights in this important 
area.12 
 The majority of survival analysis models, including the Cox proportional hazards model 
13,14 provide hazard ratios/relative risks of risk factors, leaving the baseline hazards, or absolute 
risks, unspecified. Our model is unique in that it directly provides the absolute risk, in the form 
of risk in excess to that of a reference group that is easily transformed to the absolute risk for an 
individual with a certain clinical profile and event history, for each of the MACE outcomes in this 
model (MI, stroke, HF and death), accounting for the competing nature of these cardiovascular 
(CV) events. In so doing, our model clearly delineates the risk factors for each particular CV event, 
allowing that event to have its own set of risk factors, and further delineates the risk factors for 
CVD recurrence. IHCM 1 showed that age, diabetes, a history of MI or stroke, kidney disease and 
smoking are common risk factors for all four intrinsic hazards. This is consistent with the vast 
clinical and epidemiological literature and known pathophysiology of CVD.1,3-5,7,12,15,16 It is worth 
noting that three of these risk factors are included in the original Framingham risk score, the 
other two being dyslipidemia and hypertension.17 This allows us to segue into risk factors for 
specific CV outcomes. ALLHAT’s population was comprised of hypertensive individuals aged 55 
years or above, with at least one additional CV risk factor. Because each ALLHAT participant was 
randomized to one three antihypertensive treatment arms, their blood pressure (BP) was 
managed during the trial. This likely blunted the effect of hypertension in CVD occurrence and 
recurrence in the course of the trial in comparison to that of a purely observational study, 
particularly as there were modest differences in mean blood pressure of participants between 




ALLHAT, even the small mean BP differences between treatment arms were statistically 
significant). IHCM 1 showed baseline hypertension to be a significant risk factor for stroke and 
HF, but not MI or death which suggests that stroke and HF are more sensitive to current or past 
hypertension than are MI and death. Atrial fibrillation was a significant risk factor for stroke, HF 
and death, but not for MI when adjusted for other risk factors. IHCM 1 also showed that atrial 
fibrillation conferred its greatest risk to HF and conferred comparatively lower risk to death and 
stroke. In a similar vein, returning to the risk factors common to all four outcomes, diabetes 
imparts greater risk to HF than it does to MI or stroke, but imparts its most risk overall to death. 
There has been a great deal of recent literature and studies focusing on the unique relationship 
between diabetes and HF, i.e. diabetes increases the risk of HF and worsens HF’s disease course 
and prognosis.12,15,16,18,19 Studies have also suggested that diabetes may confer more risk to HF 
than it does to (nonfatal) MI or stroke, as reflected in our analyses.12,18 Kidney disease, in a similar 
pattern confers more risk to HF than it does to MI or stroke, and its highest risk to death. These 
patterns of risk factors and their clearly demarcated conferral of risk to specific CVD outcomes – 
conferring greater risk to some events, less risk to others, and in some cases, no significant risk 
to an event or events – yields valuable insight into the nature of CVD which in turn guides 
therapeutic management tailed to an individual’s clinical profile. If a patient has certain risk 
factors, it is imperative to identify which CVD event(s) they are at highest risk for, and to select a 
treatment regimen that addresses that. For example, in an elderly male (80+ years of age) with 
diabetes, kidney disease and atrial fibrillation, the most likely nonfatal event would be HF, and 
they are of course at high risk of death as well; if this individual were to develop HF, their risk of 




conferred risk of HF compared to chlorthalidone, and lisinopril lowered risk of recurrent HF 
conferred by antecedent HF, this individual would likely benefit from an ACE inhibitor as part of 
their drug regimen (barring other contraindications) whereas amlodipine should be avoided.  
 Another important aspect of CVD is CVD-related death. Our model includes all-cause-
mortality (death) as one of the four competing events, death being the terminating event that is 
dependent on, or impacted by, one or more of the other three events (MI, stroke and HF) 
occurring beforehand. IHCM 1 yields the risk factors for death, which is particularly valuable 
because it delineates the separate risk that a particular risk factor (e.g. diabetes, kidney disease) 
confers to death, aside from the risk that that factor poses to CV events which in turn also 
increase the risk of death. In this manner, we can quantify the additional risk that diabetes, or 
atrial fibrillation or some other risk factor directly confers to death, and this risk is separate from 
that already posed by a prior CV event such as MI, stroke or HF. There are individuals who die 
from long-term complications of a chronic disease like diabetes or kidney disease without ever 
developing MI, stroke or HF. Our model provides both types of risks – the risk directly posed by 
a risk factor or disease process, and the risk posed by a prior CV event, which in turn is likely 
associated with the risk factor(s). This provides valuable risk quantification and stratification in 
both types of patients – those with risk factors and no prior CV events, and those with risk factors 
and prior CV events.  
 We will briefly mention the potential ramifications of the statistically significant 
interactions between treatment arms and risk factors shown by IHCM 2. First, the positive 
interaction between black race and lisinopril for stroke risk has been reported previously, 8,9 and 




is not as well controlled on lisinopril, resulting in increased stroke risk compared to 
chlorthalidone. The positive interaction of diabetes and amlodipine for HF risk may be partially 
reflective of the strong association between diabetes and HF; since the amlodipine arm contained 
a higher incidence of HF, this interaction may be reflective of a synergistic effect of diabetes and 
amlodipine in HF risk. Finally, the significant interactions between atrial fibrillation and both 
amlodipine and lisinopril such that both arms show a decreased risk of death compared to 
chlorthalidone, may suggest a protective role of amlodipine and lisinopril, respectively, 
compared to chlorthalidone in preventing death in those with atrial fibrillation in the long-term. 
Amlodipine was shown in a previous ALLHAT paper to lower the risk of death from atrial 
fibrillation compared to chlorthalidone.20  
 We now turn to our models’ predictive capabilities. IHCM 1 showed the significant role of 
risk factors in individuals with 0 events (i.e. study baseline), with reasonably good predictive 
capabilities at the 1, 2, 3 and 4-year time points. The predictive ability of IHCM 1 drops for 1+ 
events, 2+ events and 3+ events, with the 2+ events faring the worst at the 1-year time point. 
Prediction improves with by the 3 to 4-year time points, which suggests that the ability of events 
history to predictive future event occurrence or recurrence improves with increased time 
elapsed. IHCM 1 performs best in individuals with 4+ events, reaching AUC of 0.70 by the 3-year 
time point, which is quite good in this context. IRHCM performs better than IHCM for the 1+, 2+ 
and 4+ events, and comparatively for the 3+ events, which suggests that recurrent hazards 
covariates play a role in prediction, particularly  age (risk of death conferred by prior MI, stroke 
and HF; risk of HF conferred by prior MI), diabetes (risk of MI conferred by prior HF; risk of HF 




by prior MI) among others. IRHCM performs particularly well for individuals with 4+ events, 
reaching AUC of 0.73 at the 3-year mark, and climbing all the way up to 0.80 at the 4-year mark. 
For 1+ and 2+ events, IRHCM nearly catches up to the baseline/0 events individuals, reaching 
AUC of 0.66 by the 4-year mark. Both the IHCM 1 and the IRHCM have significant potential for 
utility as a clinical risk score or decision rule that utilizes both risk factors and event history to 
assist prediction of future events.  
 The overall pattern of both IHCM and IRHCM to perform best for individuals at baseline 
(0 events) and individuals with 4+ events suggest several things. First, the risk factors tailored to 
each event type play a dominant role in prediction. Second, individuals with 4+ events tend to 
have 1 or more HF events in their history. Since HF tends to be a late event, in the sense that it 
tends to have antecedent CV event(s) such as MI, and HF itself is a strong risk factor for future 
HF, this heightened predictive capability of both IHCM and IRHCM is likely reflective of that.    
 We now acknowledge a couple of limitations which we view as important future 
directions and extensions of our work. First, the decrease in AUC’s for the 1+, 2+ and 3+ events 
particularly at the earlier time points can be partially explained by the fact that the increased risk 
posed by an event may be ameliorated by intervention or management of risk factors at that 
time, going forward. Such interventions can be addressed by time dependent covariates, 
whereas we utilized fixed covariates for all of our analyses. Our reasons for doing so are two-fold: 
first, as in any longitudinal study, there are missing covariates both at baseline and at subsequent 
follow up time points. We already removed observations with missing baseline covariates for our 
models, which was fortunately a relatively small proportion (< 10%) and unlikely to be of 




time points would ensure removal of additional individuals with missing covariates, which would 
likely compromise our analyses, particularly given the relatively small total number of recurrent 
CVD events in the ALLHAT in-trial dataset. The handling of missing covariates, particularly in 
longitudinal studies, is a very important area of inquiry, and would be an important extension of 
our work, allowing for and potentially combining with, time-dependent analyses. Second, we 
wanted our already complex models to handle fixed covariates first in order to determine how 
well the models performed before attempting to handle time-dependent covariates, which is 
inherently more complex.  
 A second limitation was our inability to use biomarkers, in part because ALLHAT was a 
large, simple trial that did not utilize biomarkers and also because biomarkers are much more 
ubiquitous today, with many of them having been discovered or repurposed in the last decade, 
after ALLHAT’s in-trial period ended. Biomarkers such as NT-proBNP 21-23 which have been 
extensively validated for HF occurrence and recurrence and more recently linked to stroke 
occurrence and recurrence 22,23 would be a natural covariate to add to our models when the 
models are applied to longitudinal studies that measure them. Moreover, the addition of 
biomarkers as covariates would likely improve performance of our models for the individuals 
with 1+, 2+, 3+ and 4+ events. Finally, we also applied our models to the same dataset for both 
parameter estimation and to assess predictive capabilities, which did not allow us to validate our 
model on data it has never seen. This last issue can be addressed by a supervised learning 
approach, which is the subject of a future work. 
 In closing, we anticipate that our models will play a significant role in the development of 




and event history, with the exciting addition of biomarkers both old and new, that will aid every 
physician in the optimal management and treatment of CVD and related disease, including risk 
factors that are quite often chronic diseases with devastating sequelae of their own. Given the 
enormous global CVD burden mentioned in the beginning of this paper, such a tool (or tools) 
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Table 1. Full IHCM 1 covariates 
 Variable type 
 
Reference Group Additional categories or values 
Age, years Categorical Age 55-64 Age 65-79;  
Age ≥ 80 
Age* Ordinal -- 0 = Age 55-64 
1 = Age 65-74 
2 = Age 75-84 
3 = Age ≥ 85 
Diabetes (at baseline) Binary No Yes 
Previous MI or stroke Binary No Yes 
Sex Binary Female Male 
Black Binary Nonblack Black 
Previous CABG Binary No Yes 
Hypertension treated at 
baseline 
Binary No Yes 
Hypertension (at 
baseline, based on 
average of two BP 
readings, mmHg) 
Categorical SBP < 140 and DBP 
< 90 
Stage 1 hypertension  
(140 ≤ SBP < 160 and 90 < DBP < 
100);  
Stage 2 hypertension  
(SBP ≥ 160 or DBP ≥ 100)  
History of OASCVD Binary No Yes 
Atrial fibrillation 
(baseline or incident, 
detected by ECG at 
baseline or follow-up 
visit) 
Binary No Yes 
Kidney disease (at 
baseline) 
Binary GFR ≥ 60 
mL/min/1.73m2 
GFR < 60 mL/min/1.73m2 
Aspirin use (at baseline) Binary No Yes 
Smoking history Categorical Nonsmoker Past smoker;  
current smoker 
LVH by echocardiogram 
(at baseline) 
Binary No Yes 
Obesity (at baseline) Binary BMI < 30 kg/m2 BMI ≥ 30 kg/m2 
CHD (at baseline) Binary No Yes 
Major ST depression or 
T-wave inversion on ECG 
(at baseline) 
Binary No Yes 
Treatment arm Categorical Chlorthalidone Amlodipine; 
Lisinopril 
Abbreviations: BP, blood pressure; CABG, coronary artery bypass graft; CHD, coronary heart 




MI, myocardial infarction; OASCVD, other atherosclerotic cardiovascular disease; SBP, systolic 






Table 2. Modified backward selection for IHCM 1 covariates 
 MI Stroke HF Death 




Age 65-79  
Age ≥ 80 
Diabetes 












Previous MI or stroke 
Sex 
Black 
Stage 1 HTN 
Stage 2 HTN 






Age 65-79  
Age ≥ 80 
Diabetes 
Previous MI or stroke 
Black 
Previous CABG 
Stage 2 HTN 









Age 65-79  
Age ≥ 80 
Diabetes 
Previous MI or stroke 
Sex 
Black 








BS 1 REMOVE:  
Black  
ST depression 
REMOVE: CHD REMOVE: Obesityǂ REMOVE: LVH 
BS 2 -- REMOVE: OASCVDǂ REMOVE: Past smokerǂ REMOVE: Aspirin use§ 
BS 3 -- REMOVE: Stage 1 HTNǂ REMOVE: Blackǂ REMOVE: Obesityǂ 
BS 4 -- REMOVE: Blackǂ REMOVE: Age 65-79ǂ -- 
FINAL IHCM 1 Age 65-79  
Age ≥ 80 
Diabetes 
Previous MI or stroke 
Sex 
Previous CABG 
History of OASCVD 
Age⸶ 
Diabetes 
Previous MI or stroke 
Sex 
Stage 2 HTN 
Atrial fibrillation 
Kidney disease 
Age ≥ 80 
Diabetes 
Previous MI or stroke 
Previous CABG 
Stage 2 HTN 
History of OASCVD 
Atrial fibrillation 
Age 65-79  
Age ≥ 80 
Diabetes 
Previous MI or stroke 
Sex 
Black 
























Abbreviations: BS, backward selection; CABG, coronary artery bypass graft; CHD, coronary heart disease; DBP, diastolic blood pressure; 
HTN, hypertension; LVH, left ventricular hypertrophy; MI, myocardial infarction; OASCVD, other atherosclerotic cardiovascular 
disease; SBP, systolic blood pressure. 
*Refers to major ST depression or T-wave inversion on electrocardiogram (ECG). 
⸶For stroke, the age variable is ordinal as detailed in Table 1. 
ǂRemoved as a covariate to stabilize the model as the regression covariate vector could not handle all statistically significant covariates. 
§Aspirin use was found to be statistically not significant for death on the univariate IHCM, so it was removed in the second round of 
backward selection. 
‖Treatment arm found to be a statistically significant covariate; treatments arms were retained as covariates for the intrinsic hazards 




Table 3. Modified backward selection for IRHCM recurrent hazards covariates 




THE START OF 
BACKWARD 
SELECTION (BS) 













BS 1 -- REMOVE:  
Atrial fibrillation 
-- REMOVE:  






BS 2 -- -- -- REMOVE:  













Intercept Diabetes Intercept Stage 2 HTN 
Kidney disease 
Intercept 




THE START OF 
BACKWARD 
SELECTION (BS) 
Age 65-79  
Age ≥ 80 
Diabetes 
Previous MI or stroke 









History of OASCVD 
Lisinopril 












Amlodipine Past smoker 
Amlodipine 
BS 1 REMOVE:  











BS 2 -- REMOVE:  
Sex 
Aspirin use 
-- -- REMOVE:  
Previous CABG 
-- 
BS 3 -- REMOVE:  
Previous CABG 





Age 65-79  
Age ≥ 80 
Diabetes 
History of OASCVD 
Kidney disease 
Amlodipine 
Stage 2 HTN 
Atrial fibrillation 
Black 
History of OASCVD 
Lisinopril 
Age ≥ 65⸶ Ageǂ 
 
Age ≥ 65⸶ 
Stage 2 HTN 
Atrial fibrillation 
Abbreviations: BS, backward selection; CABG, coronary artery bypass graft; HTN, hypertension; LVH, left ventricular hypertrophy; MI, 
myocardial infarction; OASCVD, other atherosclerotic cardiovascular disease. 
*Kidney disease was found to be statistically significant when the full set of MM covariates was rerun, after diabetes was retained as 
a covariate for MH; retaining the full set of MM covariates improved the model goodness of fit (reflected by higher AUC’s) in spite of 
most of the covariates being statistically not significant, so it was rerun after backward selection was completed for MM, MS and MH.  
⸶Age 65-79 covariate was converted to the binary covariate Age ≥ 65 in scenarios in which the Age 65-79 covariate was retained but 
Age ≥ 80 was dropped during backward selection.  
ǂAge as an ordinal variable (refer to Table 1 for details) was found to yield an improved goodness of fit (reflected by higher AUC’s) as 





Table 4. IHCM 1 
  Baseline (excess) hazard/absolute risk* 
 Parameter Estimate (95% CI) 
 MI 𝝁𝑴   
 Intercept 0.0011 (0.0001, 0.0022) 
 Age  
    65-79 0.0035 (0.0025, 0.0045) 
    ≥ 80 0.0064 (0.0037, 0.0091) 
 Diabetes 0.0030 (0.0019, 0.0040) 
 Previous MI or stroke 0.0046 (0.0030, 0.0061) 
 Sex 0.0038 (0.0027, 0.0048) 
 Previous CABG 0.0089 (0.0066, 0.0112) 
 History of OASCVD 0.0019 (0.0007, 0.0032) 
 Kidney disease 0.0020 (0.0005, 0.0035) 
 Aspirin use 0.0018 (0.0006, 0.0029) 
 Smoking  
    Past 0.0013 (0.0002, 0.0023) 
    Current 0.0032 (0.0019, 0.0045) 
 Amlodipine -0.0003 (-0.0014, 0.0008) 
 Lisinopril -0.0001 (-0.0012, 0.0009) 
 𝜷𝑴𝑴  0.0543 (0.0473, 0.0613) 
 𝜷𝑴𝑺  0.0092 (0.0035, 0.0149) 
 𝜷𝑴𝑯  0.0123 (0.0070, 0.0175) 
Stroke 𝝁𝑺   
 Intercept 0.0007 (0.0001, 0.0012) 
 Age* 0.0023 (0.0020, 0.0026) 
 Diabetes 0.0030 (0.0022, 0.0038) 
 Previous MI or stroke 0.0041 (0.0030, 0.0052) 
 Sex 0.0013 (0.0007, 0.0019) 
 Hypertension (Stage 2) 0.0014 (0.0005, 0.0023) 
 Atrial fibrillation 0.0089 (0.0049, 0.0130) 
 Kidney disease 0.0013 (0.0002, 0.0024) 
 Smoking (Current) 0.0024 (0.0014, 0.0033) 
 Amlodipine -0.0004 (-0.0010, 0.0002) 
 Lisinopril 0.0007 (-0.0002, 0.0015) 
 𝜷𝑺𝑴  0.0031 (0.0006, 0.0056) 
 𝜷𝑺𝑺  0.0226 (0.0160, 0.0291) 
 𝜷𝑺𝑯  0.0032 (0.0002, 0.0063) 
HF 𝝁𝑯  
 Intercept 0.0006 (0.0002, 0.0010) 
 Age (≥ 80) 0.0065 (0.0038, 0.0092) 
 Diabetes 0.0038 (0.0030, 0.0047) 




 Previous CABG 0.0039 (0.0023, 0.0054) 
 Hypertension (Stage 2) 0.0016 (0.0007, 0.0025) 
 History of OASCVD 0.0016 (0.0007, 0.0025) 
 Atrial fibrillation 0.0230 (0.0174, 0.0287) 
 Kidney disease 0.0037 (0.0024, 0.0050) 
 Smoking (Current) 0.0008 (0.0001, 0.0015) 
 LVH by echocardiogram 0.0023 (0.0005, 0.0040) 
 Amlodipine 0.0020 (0.0011, 0.0029) 
 Lisinopril 0.0005 (-0.0002, 0.0011) 
 𝜷𝑯𝑴 0.0558 (0.0487, 0.0630) 
 𝜷𝑯𝑺 0.0114 (0.0057, 0.0171) 
 𝜷𝑯𝑯 0.1230 (0.1110, 0.1350) 
Death 𝝁𝑫  
 Intercept 0.0008 (-0.0001, 0.0017) 
 Age  
    65-79 0.0109 (0.0094, 0.0125) 
    ≥ 80 0.0564 (0.0503, 0.0625) 
 Diabetes 0.0085 (0.0070, 0.0101) 
 Previous MI or stroke 0.0088 (0.0067, 0.0109) 
 Sex 0.0059 (0.0044, 0.0074) 
 Black 0.0029 (0.0016, 0.0043) 
 History of OASCVD 00027 (0.0011, 0.0043) 
 Atrial fibrillation 0.0097 (0.0038, 0.0156) 
 Kidney disease 0.0145 (0.0119, 0.0172) 
 Smoking  
    Past 0.0032 (0.0018, 0.0046) 
    Current 0.0141 (0.0120, 0.0163) 
 Amlodipine 0.0003 (-0.0009, 0.0015) 
 Lisinopril -0.0002 (-0.0014, 0.0010) 
 𝜷𝑫𝑴  0.0086 (0.0036, 0.0137) 
 𝜷𝑫𝑺  0.0419 (0.0315, 0.0523) 
 𝜷𝑫𝑯  0.0678 (0.0579, 0.0777) 
Abbreviations: CABG, coronary artery bypass graft; LVH, left ventricular hypertrophy; MI, 
myocardial infarction; OASCVD, other atherosclerotic cardiovascular disease. 
*Excess hazard/absolute risk is the additional hazard/risk imparted by a risk factor compared to 




Table 5. Area under the curve for the IHCM 1. 
 
Year 0 events 1+ events 2+ events 3+ events 4+ events 








(0.54, 0.66)  
0.67 
(0.58, 0.76) 



































Table 6. IHCM 2: Interactions 
 DIABETES (N=33,357)  
  Baseline (excess) hazard/absolute risk* 
 Parameter Estimate (95% CI) 
 MI 𝝁𝑴   
 Intercept 0.0102 (0.0093, 0.0111) 
 Diabetes 0.0021 (0.0004, 0.0037) 
 Amlodipine 0.0002 (-0.0013, 0.0017) 
 Lisinopril -0.0008 (-0.0023, 0.0006) 
 Diabetes x Amlodipine -0.0018 (-0.0044, 0.0008) 
 Diabetes x Lisinopril 0.0003 (-0.0024, 0.0029) 
 𝜷𝑴𝑴  0.0559 (0.0492, 0.0626) 
 𝜷𝑴𝑺  0.0125 (0.0069, 0.0181) 
 𝜷𝑴𝑯  0.0152 (0.0100, 0.0203) 
Stroke 𝝁𝑺   
 Intercept 0.0051 (0.0044, 0.0057) 
 Diabetes 0.0031 (0.0019, 00044) 
 Amlodipine -0.0001 (-0.0011, 0.0010) 
 Lisinopril 0.0011 (<0.0001ǂ, 0.0023) 
 Diabetes x Amlodipine -0.0011 (-0.0031, 0.0009) 
 Diabetes x Lisinopril -0.0006 (-0.0028, 0.0016) 
 𝜷𝑺𝑴  0.0036 (0.0012, 0.0061) 
 𝜷𝑺𝑺  0.0246 (0.0184, 0.0309) 
 𝜷𝑺𝑯  0.0050 (0.0019, 0.0081) 
HF 𝝁𝑯   
 Intercept 0.0046 (0.0040, 0.0052) 
 Diabetes 0.0027 (0.0015, 0.0040) 
 Amlodipine 0.0018 (0.0006, 0.0029) 
 Lisinopril 0.0005 (-0.0005, 0.0016) 
 Diabetes x Amlodipine 0.0031 (0.0007, 0.0054)⸶ 
 Diabetes x Lisinopril 0.0009 (-0.0013, 0.0030) 
 𝜷𝑯𝑴  0.0578 (0.0508, 0.0648) 
 𝜷𝑯𝑺  0.0146 (0.0091, 0.0201) 
 𝜷𝑯𝑯  0.1265 (0.1151, 0.1379) 
Death 𝝁𝑫   
 Intercept 0.0253 (0.0239, 0.0268) 
 Diabetes 0.0073 (0.0046, 0.0099) 
 Amlodipine -0.0014 (-0.0037, 0.0010) 
 Lisinopril -0.0006 (-0.0029, 0.0018) 
 Diabetes x Amlodipine -0.0008 (-0.0050, 0.0034) 
 Diabetes x Lisinopril -0.0005 (-0.0048, 0.0038) 
 𝜷𝑫𝑴  0.0145 (0.0091, 0.0198) 




 𝜷𝑫𝑯  0.0725 (0.0629, 0.0821) 
 RACE (N=33,357)  
  Baseline (excess) hazard/absolute risk* 
 Parameter Estimate (95% CI) 
 MI 𝝁𝑴   
 Intercept 0.0125 (0.0115, 0.0135) 
 Black -0.0042 (-0.0057, -0.0027) 
 Amlodipine -0.0006 (-0.0022, 0.0011) 
 Lisinopril -0.0014 (-0.0030, 0.0002) 
 Black x Amlodipine 0.0005 (-0.0020, 0.0029) 
 Black x Lisinopril 0.0019 (-0.0006, 0.0043) 
 𝜷𝑴𝑴  0.0555 (0.0488, 0.0622) 
 𝜷𝑴𝑺  0.0126 (0.0070, 0.0182) 
 𝜷𝑴𝑯  0.0156 (0.0105, 0.0208) 
Stroke 𝝁𝑺   
 Intercept 0.0059 (0.0052, 0.0066) 
 Black 0.0009 (-0.0003, 0.0021) 
 Amlodipine -0.0004 (-0.0015, 0.0008) 
 Lisinopril <0.0001ǂ (-0.0012, 0.0011) 
 Black x Amlodipine -0.0003 (-0.0023, 0.0016) 
 Black x Lisinopril 0.0026 (0.0004, 0.0047)⸶ 
 𝜷𝑺𝑴  0.0036 (0.0012, 0.0061) 
 𝜷𝑺𝑺  0.0249 (0.0186, 0.0312) 
 𝜷𝑺𝑯  0.0051 (0.0020, 0.0083) 
HF 𝝁𝑯   
 Intercept 0.0054 (0.0048, 0.0061) 
 Black 0.0003 (-0.0008, 0.0015) 
 Amlodipine 0.0033 (0.0020, 0.0046) 
 Lisinopril 0.0006 (-0.0005, 0.0018) 
 Black x Amlodipine -0.0010 (-0.0031, 0.0012) 
 Black x Lisinopril 0.0005 (-0.0015, 0.0025) 
 𝜷𝑯𝑴  0.0583 (0.0513, 0.0653) 
 𝜷𝑯𝑺  0.0152 (0.0096, 0.0207) 
 𝜷𝑯𝑯  0.1269 (0.1154, 0.1383) 
Death 𝝁𝑫   
 Intercept 0.0271 (0.0256, 0.0286) 
 Black 0.0022 (-0.0003, 0.0048) 
 Amlodipine -0.0020 (-0.0044, 0.0004) 
 Lisinopril -0.0017 (-0.0041, 0.0007) 
 Black x Amlodipine 0.0010 (-0.0031, 0.0051) 
 Black x Lisinopril 0.0025 (-0.0017, 0.0067) 
 𝜷𝑫𝑴  0.0146 (0.0092, 0.0199) 




 𝜷𝑫𝑯  0.0730 (0.0634, 0.0826) 
 ATRIAL FIBRILLATION (N=32,026)  
  Baseline (excess) hazard/absolute risk* 
 Parameter Estimate (95% CI) 
 MI 𝝁𝑴   
 Intercept 0.0111 (0.0103, 0.0119) 
 Atrial fibrillation 0.0011 (-0.0041, 0.0063) 
 Amlodipine -0.0005 (-0.0017, 0.0008) 
 Lisinopril -0.0009 (-0.0022, 0.0004) 
 Atrial fibrillation x Amlodipine 0.0044 (-0.0046, 0.0134) 
 Atrial fibrillation x Lisinopril 0.0059 (-0.0034, 0.0153) 
 𝜷𝑴𝑴  0.0560 (0.0492, 0.0628) 
 𝜷𝑴𝑺  0.0121 (0.0064, 0.0177) 
 𝜷𝑴𝑯  0.0156 (0.0103, 0.0208) 
Stroke 𝝁𝑺   
 Intercept 0.0060 (0.0054, 0.0066) 
 Atrial fibrillation 0.0097 (0.0038, 0.0155) 
 Amlodipine -0.0005 (-0.0014, 0.0004) 
 Lisinopril 0.0009 (-0.0001, 0.0019) 
 Atrial fibrillation x Amlodipine 0.0014 (-0.0080, 0.0108) 
 Atrial fibrillation x Lisinopril 0.0008 (-0.0089, 0.0105) 
 𝜷𝑺𝑴  0.0039 (0.0014, 0.0065) 
 𝜷𝑺𝑺  0.0241 (0.0178, 0.0304) 
 𝜷𝑺𝑯  0.0040 (0.0010, 0.0071) 
HF 𝝁𝑯   
 Intercept 0.0051 (0.0046, 0.0056) 
 Atrial fibrillation 0.0265 (0.0179, 0.0350) 
 Amlodipine 0.0027 (0.0017, 0.0037) 
 Lisinopril 0.0009 (<0.0001ǂ, 0.0018) 
 Atrial fibrillation x Amlodipine 0.0021 (-0.0117, 0.0160) 
 Atrial fibrillation x Lisinopril -0.0105 (-0.0231, 0.0020) 
 𝜷𝑯𝑴  0.0580 (0.0510, 0.0650) 
 𝜷𝑯𝑺  0.0132 (0.0077, 0.0187) 
 𝜷𝑯𝑯  0.1251 (0.1135, 0.1366) 
Death 𝝁𝑫   
 Intercept 0.0263 (0.0251, 0.0275) 
 Atrial fibrillation 0.0260 (0.0153, 0.0366) 
 Amlodipine -0.0008 (-0.0028, 0.0011) 
 Lisinopril -0.0003 (-0.0023, 0.0017) 
 Atrial fibrillation x Amlodipine -0.0189 (-0.0337, -0.0040)⸶ 
 Atrial fibrillation x Lisinopril -0.0186 (-0.0341, -0.0031)⸶ 
 𝜷𝑫𝑴  0.0145 (0.0091, 0.0198) 




 𝜷𝑫𝑯  0.0720 (0.0624, 0.0816) 
Abbreviations: HF, heart failure; MI, myocardial infarction. 
*Excess hazard/absolute risk is the additional hazard/risk imparted by a risk factor compared to 
its reference group. 
⸶Statistically significant interaction 





Table 7. Final IRHCM  
  Baseline (excess) hazard/absolute risk* 
 Parameter Estimate (95% CI) 
 MI 𝝁𝑴   
 Intercept 0.0012 (0.0001, 0.0022) 
 Age  
    65-79 0.0036 (0.0026, 0.0045) 
    ≥ 80 0.0066 (0.0039, 0.0093) 
 Diabetes 0.0029 (0.0018, 0.0039) 
 Previous MI or stroke 0.0046 (0.0030, 0.0061) 
 Sex 0.0037 (0.0026, 0.0047) 
 Previous CABG 0.0089 (0.0066, 0.0112) 
 History of OASCVD 0.0019 (0.0007, 0.0032) 
 Kidney disease 0.0019 (0.0004, 0.0034) 
 Aspirin use 0.0018 (0.0007, 0.0030) 
 Smoking  
    Past 0.0012 (0.0002, 0.0023) 
    Current 0.0032 (0.0019, 0.0045) 
 Amlodipine -0.0003 (-0.0014, 0.0008) 
 Lisinopril -0.0002 (-0.0012, 0.0009) 
 𝜷𝑴𝑴   
 Intercept 0.0342 (0.0228, 0.0456) 
 Sex 0.0218 (0.0079, 0.0357) 
 Kidney disease 0.0246 (0.0061, 0.0431) 
 𝜷𝑴𝑺  0.0090 (0.0034, 0.0147) 
 𝜷𝑴𝑯   
 Intercept 0.0060 (<0.0001ǂ, 0.0120) 
 Diabetes 0.0136 (0.0029, 0.0242) 
Stroke 𝝁𝑺   
 Intercept 0.0007 (0.0001, 0.0012) 
 Age⸶ 0.0023 (0.0020, 0.0026) 
 Diabetes 0.0030 (0.0022, 0.0038) 
 Previous MI or stroke 0.0041 (0.0030, 0.0052) 
 Sex 0.0013 (0.0007, 0.0019) 
 Hypertension (Stage 2) 0.0014 (0.0005, 0.0023) 
 Atrial fibrillation 0.0089 (0.0049, 0.0130) 
 Kidney disease 0.0013 (0.0002, 0.0024) 
 Smoking (Current) 0.0024 (0.0014, 0.0033) 
 Amlodipine -0.0004 (-0.0010, 0.0002) 
 Lisinopril 0.0007 (-0.0002, 0.0015) 
 𝜷𝑺𝑴  0.0031 (0.0006, 0.0056) 
 𝜷𝑺𝑺  0.0226 (0.0160, 0.0291) 




   
HF 𝝁𝑯  
 Intercept 0.0007 (0.0002, 0.0011) 
 Age (≥ 80) 0.0062 (0.0036, 0.0088) 
 Diabetes 0.0037 (0.0029, 0.0046) 
 Previous MI or stroke 0.0043 (0.0031, 0.0054) 
 Previous CABG 0.0039 (0.0023, 0.0055) 
 Hypertension (Stage 2) 0.0016 (0.0008, 0.0025) 
 History of OASCVD 0.0015 (0.0006, 0.0024) 
 Atrial fibrillation 0.0228 (0.0172, 0.0284) 
 Kidney disease 0.0036 (0.0023, 0.0049) 
 Smoking (Current) 0.0008 (0.0001, 0.0016) 
 LVH by echocardiogram 0.0023 (0.0005, 0.0040) 
 Amlodipine 0.0020 (0.0011, 0.0028) 
 Lisinopril 0.0005 (-0.0002, 0.0012) 
 𝜷𝑯𝑴  
 Intercept 0.0124 (0.0033, 0.0216) 
 Age  
    65-79 0.0182 (0.0056, 0.0308) 
    ≥ 80 0.0627 (0.0232, 0.1022) 
 Diabetes 0.0431 (0.0280, 0.0582) 
 History of OASCVD 0.0183 (0.0023, 0.0342) 
 Kidney disease 0.0275 (0.0081, 0.0470) 
 Amlodipine 0.0160 (0.0005, 0.0314) 
 𝜷𝑯𝑺  0.0114 (0.0058, 0.0171) 
 𝜷𝑯𝑯  
 Intercept 0.1278 (0.1135, 0.1422) 
 Lisinopril -0.0302 (-0.0553, -0.0051) 
Death 𝝁𝑫  
 Intercept 0.0009 (-0.0001, 0.0018) 
 Age  
    65-79 0.0104 (0.0089, 0.0120) 
    ≥ 80 0.0551 (0.0491, 0.0612) 
 Diabetes 0.0088 (0.0072, 0.0104) 
 Previous MI or stroke 0.0089 (0.0068, 0.0110) 
 Sex 0.0061 (0.0046, 0.0076) 
 Black 0.0029 (0.0015, 0.0043) 
 History of OASCVD 0.0027 (0.0011, 0.0043) 
 Atrial fibrillation 0.0093 (0.0034, 0.0151) 
 Kidney disease 0.0146 (0.0119, 0.0172) 
 Smoking  
    Past 0.0033 (0.0019, 0.0047) 




 Amlodipine 0.0003 (-0.0009, 0.0015) 
 Lisinopril -0.0002 (-0.0014, 0.0010) 
 𝜷𝑫𝑴   
 Intercept -0.0013 (-0.0069, 0.0042) 
 Age ≥ 65 0.0176 (0.0085, 0.0268) 
 𝜷𝑫𝑺   
 Intercept 0.0228 (0.0114, 0.0342) 
 Age⸶ 0.0228 (0.0166, 0.0290) 
 𝜷𝑫𝑯   
 Intercept 0.0524 (0.0365, 0.0684) 
 Age ≥ 65 0.0203 (0.0002, 0.0403) 
*Excess hazard/absolute risk is the additional hazard/risk imparted by a risk factor compared to 
its reference group. 
⸶Age as an ordinal variable (see Table 1 for details) was found to yield an improved goodness of 
fit (reflected by higher AUC’s) as compared to Age ≥ 80, so ordinal Age was retained for the final 
IRHCM. 





Table 8. Area under the curve for the IRHCM. 
 
Year 0 events 1+ events 2+ events 3+ events 4+ events 
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CHAPTER 4: JOURNAL ARTICLE 3 
A Supervised Learning Approach to a Competing Risk Model for Multi-type Recurrent Events 
ABSTRACT 
We adopt a supervised learning approach, utilizing bagged training sets and test sets to stabilize 
and validate our models described previously (IHCM 1 and IRHCM) to quantify multi-type 
recurrent events hazards in a competing risk framework, with death as the dependent 
terminating event. A total of 250 bagged training sets at 70% and 60% yielded similar tuned 
parameter estimates for IHCM 1, with smaller standard errors for 70% bagging, which showed 
lisinopril to impart a statistically significant intrinsic hazard of stroke and HF compared to 
chlorthalidone. Bagging at 70% and 60% showed similar performance in predictive capabilities 
on the full ALLHAT dataset and on corresponding test sets (30% and 40%, respectively). IRHCM 
bagged training sets at 70% yielded tuned parameter estimates with smaller standard errors 
compared to previous IRHCM results and similar results for lisinopril as bagged IHCM 1 (70%). 
IRHCM also performed similarly on the full dataset and relatively well on its corresponding test 
sets (30%). Bagging in a supervised learning framework accomplished our aims of stabilizing and 
validating our models in conjunction with variable selection. 
INTRODUCTION 
In our previous work, we first proposed a dynamic competing risk model for multi-type 
recurrent events and applied the model in the important setting of cardiovascular disease (CVD) 
to the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) 
study.1 We subsequently extended the model to incorporate CVD risk factors as covariates for 




recurrent CVD events [myocardial infarction (MI), stroke, heart failure (HF) and death from any 
cause (death)] with significant potential to develop a CV risk assessment/risk score tailored to 
the individual’s clinical profile, that would be widely utilized by physicians for therapeutic 
management.2 In this paper, we will implement a supervised learning approach to further 
develop our model in the following ways: 1) tune the estimated parameters for the models 
described in our second paper, IHCM 1 and IRHCM 2; 2) utilize the tuned parameters and their 
newly constructed 95% confidence intervals (CI) for potential variable selection; and 3) validate 
the model with the use of training sets and test sets.  
METHODS 
Parameter tuning and construction of confidence interval 
 All of our statistical analyses were carried out in R 3.4.4 (R Foundation for Statistical 
Computing, Vienna, Austria). For IHCM 1, we first split the full ALLHAT dataset  (𝑛 = 30,295) 
described in detail in our second paper 2 into 4 subsets: individuals that had 0 events throughout 
the in-trial portion of ALLHAT (𝑛 = 26,937); individuals who had 1 event (𝑛 = 2,418); 
individuals who had 2 events (𝑛 = 570); and individuals who had 3 or more events (𝑛 = 370). 
We then created 250 bagged training sets by randomly selecting 70% of observations from each 
of the 4 subsets, i.e. we randomly selected 70% of observations (𝑛 = 18,856) from individuals 
who had 0 events, 70% of observations (𝑛 = 1,693) from individuals who had 1 event, 70% of 
observations (𝑛 = 399) from individuals who had 2 events, and 70% of observations (𝑛 = 259) 
from individuals who had 3+ events, and combining all of these observations into a single bagged 




with respect to preserving the relative proportions of CVD events of the original ALLHAT dataset. 
This procedure was repeated for a total of 250 bagged training sets.  
 We fitted IHCM 1 for each bagged training set to obtain the parameter estimates via the 
modified Newton Raphson optimization algorithm described in our first paper.1 We obtained the 
final parameter estimates for IHCM 1 by taking the mean of the 250 bagged parameter estimates, 
and the standard error of each final parameter estimate by taking the standard deviation of the 
250 bagged parameter estimates for each parameter. We then constructed the 95% Wald CI for 
each parameter using the final parameter estimate and its standard error. 
 We then applied the IHCM 1 parameter estimates, tuned by the 250 bagged training sets, 
to the original ALLHAT dataset (𝑛 = 30,295) to assess the goodness of fit for IHCM 1 using the 
approach that we described in our previous papers.1,2 Very briefly, we predicted event-free 
survival at 1-year, 2-year, 3-year and 4-year increments for all individuals at baseline, individuals 
that had 1 or more events, individuals that had 2 or more events, individuals that had 3 or more 
events and individuals that had 4 or more events. The ALLHAT dataset contained the binary result 
of whether or not that individual had any event, nonfatal or fatal, within that time frame; 
censored observations were handled in a manner identical to that detailed in our previous 
work.1,2 The estimated area under the curve (AUC) and its standard error of the resulting receiver 
operating characteristic (ROC) curve for each time frame and number of events were obtained 
and this AUC was a measure of goodness of fit for the model.  
 We repeated the above procedures for ICHM 1 with 250 bagged training sets of 60%, i.e. 
each training set contained randomly selected 60% of observations from each of the 4 subsets 




1,451) from individuals who had 1 event, 60% of observations (𝑛 = 342) from individuals who 
had 2 events, and 60% of observations (𝑛 = 222) from individuals who had 3+ events, and 
combining all of these observations into a single bagged training set (𝑛 = 18,177)]. The final 
parameter estimates and their 95% CI’s were constructed in the same manner and the goodness 
of fit assessed. 
 We repeated the entire procedure for the IRHCM described in our second paper 2 to 
obtain 200 bagged training sets, the final IRHCM parameter estimates and their 95% CI’s and 
goodness of fit. IRHCM has more parameters (77) than IHCM 1 (64) and takes longer to converge; 
due to constraints of computing speed and resources, we opted for 200 bagged training sets for 
IRHCM.  
Supervised learning and model validation 
 For IHCM 1, each bagged training set (70% and 60%, respectively) had a corresponding 
test set (30% and 40%, respectively). The IHCM 1 parameters estimated from each bagged 
training set were applied to its corresponding test set (which was data that the model had never 
seen before, having been trained on the training set only). The resulting goodness of fit for the 
test set was obtained in the same manner described in the preceding section, with a slight 
adjustment: due to the small size of the test set (30%, 𝑛 = 9,088; and 40%, 𝑛 = 12,118), we 
predicted event-free survival at 1-year, 2-year and 3-year increments for all individuals at 
baseline (30%, 𝑛 = 9,088; and 40%, 𝑛 = 12,118), individuals that had 1 or more events (30%, 
𝑛 = 1,007; and 40%, 𝑛 = 1,343), individuals that had 2 or more events (30%, 𝑛 = 282; and 40%, 
𝑛 = 376) and individuals that had 3 or more events (30%, 𝑛 = 111; and 40%, 𝑛 = 148). The 




averaged, and the resulting mean goodness of fit AUC was the final estimate. The standard errors 
of each AUC final estimate were obtained by taking the standard deviation of the corresponding 
250 bagged goodness of fit AUC’s, and subsequently used to construct the 95% Wald CI for each 
AUC estimate. 
 The above procedure was repeated for the IRHCM for the 200 bagged training sets (70%) 
and their corresponding test sets (30%) and the final goodness of fit AUC’s and their standard 
errors calculated, with resulting 95% Wald CI for each AUC.  
RESULTS 
 The tuned parameters and their 95% CI’s of IHCM 1 for both the 70% and 60% bagged 
training sets are reported in Table 1. The tuned parameter estimates for the 70% and 60% bagged 
training sets are very close or identical to one another. The corresponding standard errors for the 
60% bagged sets are larger for every parameter estimate than that of the 70% bagged sets; as a 
result, the corresponding 95% CI for each parameter is wider for the 60% bagged sets than the 
70% bagged sets. The lisinopril treatment arm compared to chlorthalidone imparts a statistically 
significant intrinsic hazard for stroke [0.0007 (<0.00011, 0.0013)] and HF [0.0005 (<0.00011, 
0.0009)], respectively for the 70% bagged sets; in contrast, lisinopril does not impart a statistically 
significant hazard compared to chlorthalidone for stroke and HF in the 60% bagged sets. Both the 
tuned parameters of the 70% (Table 2a) and the 60% bagged sets (Table 2b) yield essentially 
identical AUC’s as goodness of fit measures when applied to the original ALLHAT dataset 
(𝑛 = 30,295). The 70% bagged training set parameters’ performance on their corresponding 
                                                          





30% test sets (Table 3a) is nearly identical to that of the 60% bagged training set parameters’ 
performance on their 40% test sets (Table 3b), with the 70% performing slightly better for 
individuals with 2+ events at the 1-year mark, and for individuals with 3+ events at the 3-year 
mark. Both the 70% and the 60% bagged training set parameters essentially retain their 
predictive abilities for individuals at baseline (0 events), with a decrease in prediction for 
individuals with 1+ events, further decrease in prediction for individuals with 2+ events, and then 
increase in prediction for individuals with 3+ events, which continues to improve from the 1-year 
mark to the 3-year mark, at which point it essentially catches up to the 3-year mark for all 
individuals (0 events). 
 The tuned parameters and their 95% CI’s of IRHCM for the 200 bagged training sets (70%) 
are reported in Table 4. Similar to the bagged IHCM 1, the lisinopril treatment arm compared to 
chlorthalidone imparts a statistically significant intrinsic hazard for stroke [0.0007 (<0.00011, 
0.0013)] and HF [0.0005 (0.0001, 0.0010)], respectively. In contrast, the IRHCM from our previous 
paper 2 did not show lisinopril (compared to chlorthalidone) as a statistically significant covariate 
for intrinsic hazard of stroke, nor HF. The tuned parameters of IRHCM yielded by the bagged 
training sets is overall very similar or identical to IRHCM of our previous paper, 2 with smaller 
standard errors reflected in narrower 95% CI’s for the bagged IRHCM parameters. Moreover, the 
tuned IRHCM parameters of the 70% bagged sets (Table 5) yield identical AUC’s as goodness of 
fit measures when applied to the original ALLHAT dataset (𝑛 = 30,295), as the original IRHCM 
parameters reported previously.2 The IRHCM 70% bagged training set parameters’ performance 
on their corresponding 30% test sets is reported in Table 6. IRHCM performs comparatively to 




slightly outperforms IHCM 1 for individuals with 1+ and 2+ events, and slightly decreases in 
predictive performance for individuals with 3+ events compared to IHCM 1.   
DISCUSSION 
 In this paper, we wished to further develop our model in several important ways: first, we 
wanted to improve our parameter estimates for our previously described models (IHCM 1 and 
IRHCM) with the potential for variable selection. We also wanted to stabilize the models by 
reducing the standard errors of the parameter estimates and finally, we wished to validate our 
models by assessing its predictive capabilities on data it has never seen. 
 To accomplish all of these aims, we elected a supervised learning approach by training 
our models on a subset of the full ALLHAT dataset (𝑛 = 30,295) utilized in our second paper 2 
and then running the trained models on the remaining subset. Supervised learning is a well-
established type of machine learning algorithm that can address and improve common problems 
of statistical models including overfitting.3 Specifically, bagging (also known as bootstrap 
aggregating) is a machine learning algorithm designed to improve the stability and accuracy of 
models and reduces variance and overfitting.4 It is easily incorporated into a supervised learning 
approach in the manner described here. 
 Our bagged training sets (70%) yielded stable parameter estimates for IHCM and IRHCM 
with reduced standard errors which resulted in tighter 95% CI’s for each parameter estimate. 
This directly resulted in a type of variable selection, in that the lisinopril treatment arm (in 
comparison to chlorthalidone) was found to impart a statistically significant intrinsic hazard for 
stroke and HF. A statistically significant higher risk of stroke in the lisinopril arm compared to 




chlorthalidone have been reported previously.5,6 Our updated IHCM 1 and IRHCM results are thus 
consistent with previous ALLHAT results. Due to the tuned parameter estimates for IHCM 1 and 
IRHCM in this paper being very close or identical to our previously reported IHCM 1 and IRHCM 
results, they performed comparatively with respect to goodness of fit measures on the full 
ALLHAT dataset. 
 We also validated our model by running each model trained on the bagged training set, 
on its corresponding test set. Both the 70% and the 60% training set models for both IHCM 1 and 
IRHCM performed comparatively with respect to their predictive capabilities on their 30% and 
40% test sets, respectively. IHCM 1 and IRHCM retained their predictive abilities on the test set, 
i.e. data it has never seen before, for all individuals at baseline (0 events), with similar decreases 
for individuals with 1+ and 2+ events, and again increasing for individuals with 3+ events, and 
improvement with later time points (3-year mark vs 1-year mark). These results suggest that our 
model is robust and performs relatively well on data it has never seen, and does not suffer from 
the common problem of overfitting. 
 We acknowledge one or two limitations that should be considered as future directions 
and further extensions of our work. Due to the computing resources and length of time required 
for our models to converge, particularly the IRHCM, we limited our number of bagged training 
sets to 250 and 200, respectively for IHCM 1 and IRHCM. It is likely and in fact probable, that our 
models would have been improved if we had performed 1,000 bagged training sets which would 
have resulted in more stable estimates with smaller standard errors and tighter 95 CI’s. This may 
have yielded improved goodness of fit measures on the original ALLHAT dataset, whereas our 




predictive capabilities for individuals with 3+ events compared to IHCM 1, and this was likely 
driven by IRHCM performing slightly worse in individuals with 3 events; since individuals who had 
4+ events were combined with this group, IRHCM’s likely better performance in that group was 
not captured. In any case, the lowered performance for both IHCM 1 and IRHCM for individuals 
with 1+, 2+ and 3+ events compared to all individuals at baseline (0 events) and individuals with 
4+ events has been discussed at length in our previous paper, with ways to address it in future 
work.2     
            Overall, we accomplished our aims of stabilizing our model, with reduced standard errors 
and tighter confidence intervals that resulted in a type of variable selection with important 
ramifications (i.e. lisinopril imparts a statistically significant intrinsic hazard for stroke and HF, 
relative to chlorthalidone). Furthermore, we validated our model by showing its ability to 
perform relatively well and retain its predictive capabilities in data it has never seen, and in so 
doing, we directly addressed a limitation in our previous work in which we trained the models on 
the full dataset and assessed prediction on the same dataset. Bagging in a supervised learning 
framework is a valuable and powerful tool to improve and stabilize existing models, as well as 
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Table 1. IHCM, tuned parameters from 250 bagged datasets 
  Baseline (excess) hazard/absolute risk* 
  70/30 60/40 
 Parameter Estimate (95% CI) Estimate (95% CI) 
 MI 𝝁𝑴    
 Intercept 0.0011 (0.0003, 0.0018) 0.0010 (0.0001, 0.0020) 
 Age   
    65-79 0.0035 (0.0028, 0.0042) 0.0035 (0.0026, 0.0044) 
    ≥ 80 0.0064 (0.0047, 0.0080) 0.0064 (0.0042, 0.0085) 
 Diabetes 0.0030 (0.0023, 0.0037) 0.0031 (0.0022, 0.0039) 
 Previous MI or stroke 0.0046 (0.0036, 0.0056) 0.0046 (0.0034, 0.0058) 
 Sex 0.0038 (0.0031, 0.0044) 0.0038 (0.0030, 0.0046) 
 Previous CABG 0.0089 (0.0074, 0.0103) 0.0089 (0.0072, 0.0106) 
 History of OASCVD 0.0020 (0.0011, 0.0028) 0.0020 (0.0009, 0.0031) 
 Kidney disease 0.0019 (0.0009, 0.0029) 0.0019 (0.0007, 0.0032) 
 Aspirin use 0.0018 (0.0010, 0.0026) 0.0018 (0.0008, 0.0028) 
 Smoking   
    Past 0.0013 (0.0005, 0.0020) 0.0013 (0.0004, 0.0022) 
    Current 0.0033 (0.0024, 0.0042) 0.0033 (0.0022, 0.0044) 
 Amlodipine -0.0003 (-0.0011, 0.0004) -0.0003 (-0.0013, 0.0006) 
 Lisinopril -0.0001 (-0.0009, 0.0006) -0.0001 (-0.0011, 0.0008) 
 𝜷𝑴𝑴  0.0541 (0.0499, 0.0582) 0.0540 (0.0492, 0.0589) 
 𝜷𝑴𝑺  0.0091 (0.0053, 0.0129) 0.0092 (0.0043, 0.0141) 
 𝜷𝑴𝑯  0.0123 (0.0090, 0.0155) 0.0122 (0.0081, 0.0163) 
Stroke 𝝁𝑺    
 Intercept 0.0006 (0.0002, 0.0011) 0.0006 (<0.0001, 0.0013) 
 Age* 0.0023 (0.0019, 0.0027) 0.0023 (0.0018, 0.0028) 
 Diabetes 0.0030 (0.0025, 0.0036) 0.0031 (0.0023, 0.0038) 
 Previous MI or stroke 0.0041 (0.0033, 0.0049) 0.0041 (0.0032, 0.0050) 
 Sex 0.0013 (0.0008, 0.0019) 0.0014 (0.0007, 0.0021) 
 Hypertension (Stage 2) 0.0014 (0.0008, 0.0020) 0.0014 (0.0006, 0.0022) 
 Atrial fibrillation 0.0090 (0.0061, 0.0118) 0.0090 (0.0056, 0.0125) 
 Kidney disease 0.0013 (0.0005, 0.0021) 0.0013 (0.0004, 0.0023) 
 Smoking (Current) 0.0024 (0.0018, 0.0030) 0.0024 (0.0016, 0.0032) 
 Amlodipine -0.0005 (-0.0012, 0.0002) -0.0005 (-0.0014, 0.0003) 
 Lisinopril 0.0007 (<0.0001ǂ, 0.0013)⸶ 0.0007 (-0.0001, 0.0014) 
 𝜷𝑺𝑴  0.0032 (0.0014, 0.0049) 0.0032 (0.0008, 0.0055) 
 𝜷𝑺𝑺  0.0227 (0.0186, 0.0267) 0.0227 (0.0177, 0.0277) 
 𝜷𝑺𝑯  0.0032 (0.0012, 0.0052) 0.0033 (0.0007, 0.0059) 
HF 𝝁𝑯   
 Intercept 0.0006 (0.0004, 0.0009) 0.0006 (0.0003, 0.0010) 




 Diabetes 0.0038 (0.0033, 0.0044) 0.0039 (0.0032, 0.0045) 
 Previous MI or stroke 0.0042 (0.0033, 0.0050) 0.0041 (0.0032, 0.0051) 
 Previous CABG 0.0039 (0.0028, 0.0050) 0.0039 (0.0025, 0.0053) 
 Hypertension (Stage 2) 0.0016 (0.0010, 0.0022) 0.0016 (0.0009, 0.0024) 
 History of OASCVD 0.0016 (0.0010, 0.0022) 0.0016 (0.0008, 0.0023) 
 Atrial fibrillation 0.0229 (0.0194, 0.0264) 0.0229 (0.0187, 0.0271) 
 Kidney disease 0.0037 (0.0028, 0.0046) 0.0037 (0.0025, 0.0048) 
 Smoking (Current) 0.0008 (0.0003, 0.0013) 0.0008 (0.0002, 0.0015) 
 LVH by 
echocardiogram 
0.0023 (0.0011, 0.0035) 0.0023 (0.0009, 0.0038) 
 Amlodipine 0.0019 (0.0014, 0.0025) 0.0019 (0.0012, 0.0027) 
 Lisinopril 0.0005 (<0.0001ǂ, 0.0009)⸶ 0.0005 (-0.0001, 0.0011) 
 𝜷𝑯𝑴 0.0556 (0.0507, 0.0606) 0.0557 (0.0496, 0.0618) 
 𝜷𝑯𝑺 0.0115 (0.0077, 0.0153) 0.0115 (0.0071, 0.0159) 
 𝜷𝑯𝑯 0.1227 (0.1143, 0.1312) 0.1226 (0.1115, 0.1337) 
Death 𝝁𝑫   
 Intercept 0.0008 (-0.0002, 0.0017) 0.0007 (-0.0005, 0.0020) 
 Age   
    65-79 0.0109 (0.0099, 0.0120) 0.0109 (0.0097, 0.0122) 
    ≥ 80 0.0563 (0.0525, 0.0601) 0.0563 (0.0515, 0.0611) 
 Diabetes 0.0085 (0.0074, 0.0095) 0.0085 (0.0071, 0.0098) 
 Previous MI or stroke 0.0088 (0.0076, 0.0101) 0.0088 (0.0071, 0.0105) 
 Sex 0.0060 (0.0049, 0.0070) 0.0060 (0.0046, 0.0073) 
 Black 0.0030 (0.0021, 0.0039) 0.0030 (0.0019, 0.0042) 
 History of OASCVD 00028 (0.0017, 0.0038) 00028 (0.0014, 0.0042) 
 Atrial fibrillation 0.0097 (0.0061, 0.0133) 0.0097 (0.0051, 0.0144) 
 Kidney disease 0.0146 (0.0129, 0.0163) 0.0146 (0.0123, 0.0169) 
 Smoking   
    Past 0.0033 (0.0023, 0.0044) 0.0034 (0.0021, 0.0047) 
    Current 0.0142 (0.0128, 0.0156) 0.0143 (0.0125, 0.0160) 
 Amlodipine 0.0003 (-0.0008, 0.0014) 0.0003 (-0.0011, 0.0017) 
 Lisinopril -0.0004 (-0.0016, 0.0009) -0.0004 (-0.0020, 0.0011) 
 𝜷𝑫𝑴  0.0086 (0.0053, 0.0120) 0.0085 (0.0043, 0.0127) 
 𝜷𝑫𝑺  0.0418 (0.0347, 0.0488) 0.0419 (0.0336, 0.0502) 
 𝜷𝑫𝑯  0.0679 (0.0613, 0.0745) 0.0679 (0.0599, 0.0759) 
*Excess hazard/absolute risk is the additional hazard/risk imparted by a risk factor compared to 
its reference group. 
⸶Statistically significant covariate from bagging 





Table 2a. Area under the curve for the tuned IHCM (70/30) 
 
Year 0 events 1+ events 2+ events 3+ events 4+ events 








(0.54, 0.66)  
0.67 
(0.58, 0.76) 
































Table 2b. Area under the curve for the tuned IHCM (60/40) 
 
Year 0 events 1+ events 2+ events 3+ events 4+ events 








(0.54, 0.66)  
0.67 
(0.58, 0.76) 




































Table 3a. Area under the curve for IHCM test set (70/30) 
 
Year 0 events 1+ events 2+ events 3+ events 








(0.50, 0.70)  



















Table 3b. Area under the curve for IHCM test set (60/40) 
 
Year 0 events 1+ events 2+ events 3+ events 








(0.53, 0.68)  




















Table 4. IRHCM, tuned parameters from 200 bagged datasets (70/30) 
  Baseline (excess) hazard/absolute risk* 
 Parameter Estimate (95% CI) 
 MI 𝝁𝑴   
 Intercept 0.0011 (0.0004, 0.0018) 
 Age  
    65-79 0.0035 (0.0029, 0.0042) 
    ≥ 80 0.0066 (0.0048, 0.0083) 
 Diabetes 0.0029 (0.0022, 0.0036) 
 Previous MI or stroke 0.0046 (0.0036, 0.0056) 
 Sex 0.0037 (0.0030, 0.0044) 
 Previous CABG 0.0089 (0.0074, 0.0103) 
 History of OASCVD 0.0019 (0.0011, 0.0028) 
 Kidney disease 0.0018 (0.0008, 0.0028) 
 Aspirin use 0.0018 (0.0010, 0.0027) 
 Smoking  
    Past 0.0013 (0.0005, 0.0020) 
    Current 0.0033 (0.0024, 0.0042) 
 Amlodipine -0.0003 (-0.0011, 0.0004) 
 Lisinopril -0.0002 (-0.0009, 0.0006) 
 𝜷𝑴𝑴   
 Intercept 0.0340 (0.0256, 0.0424) 
 Sex 0.0217 (0.0124, 0.0310) 
 Kidney disease 0.0242 (0.0102, 0.0382) 
 𝜷𝑴𝑺  0.0089 (0.0050, 0.0129) 
 𝜷𝑴𝑯   
 Intercept 0.0060 (0.0020, 0.0099) 
 Diabetes 0.0138 (0.0066, 0.0210) 
Stroke 𝝁𝑺   
 Intercept 0.0006 (0.0002, 0.0011) 
 Age* 0.0023 (0.0019, 0.0027) 
 Diabetes 0.0031 (0.0025, 0.0036) 
 Previous MI or stroke 0.0041 (0.0033, 0.0049) 
 Sex 0.0013 (0.0008, 0.0018) 
 Hypertension (Stage 2) 0.0014 (0.0007, 0.0020) 
 Atrial fibrillation 0.0089 (0.0060, 0.0117) 
 Kidney disease 0.0013 (0.0006, 0.0021) 
 Smoking (Current) 0.0024 (0.0018, 0.0030) 
 Amlodipine -0.0005 (-0.0012, 0.0002) 
 Lisinopril 0.0007 (<0.0001ǂ, 0.0013)⸶ 
 𝜷𝑺𝑴  0.0032 (0.0014, 0.0050) 
 𝜷𝑺𝑺  0.0227 (0.0186, 0.0267) 




   
HF 𝝁𝑯  
 Intercept 0.0007 (0.0004, 0.0009) 
 Age (≥ 80) 0.0062 (0.0044, 0.0079) 
 Diabetes 0.0037 (0.0032, 0.0043) 
 Previous MI or stroke 0.0042 (0.0034, 0.0050) 
 Previous CABG 0.0040 (0.0029, 0.0050) 
 Hypertension (Stage 2) 0.0017 (0.0011, 0.0023) 
 History of OASCVD 0.0015 (0.0009, 0.0022) 
 Atrial fibrillation 0.0227 (0.0192, 0.0261) 
 Kidney disease 0.0036 (0.0027, 0.0045) 
 Smoking (Current) 0.0009 (0.0003, 0.0014) 
 LVH by echocardiogram 0.0023 (0.0011, 0.0035) 
 Amlodipine 0.0019 (0.0013, 0.0025) 
 Lisinopril 0.0005 (0.0001, 0.0010)⸶ 
 𝜷𝑯𝑴  
 Intercept 0.0126 (0.0063, 0.0189) 
 Age  
    65-79 0.0178 (0.0093, 0.0262) 
    ≥ 80 0.0628 (0.0319, 0.0937) 
 Diabetes 0.0430 (0.0322, 0.0538) 
 History of OASCVD 0.0189 (0.0070, 0.0308) 
 Kidney disease 0.0273 (0.0128, 0.0417) 
 Amlodipine 0.0160 (0.0052, 0.0268) 
 𝜷𝑯𝑺  0.0116 (0.0077, 0.0154) 
 𝜷𝑯𝑯  
 Intercept 0.1274 (0.1170, 0.1377) 
 Lisinopril -0.0300 (-0.0509, -0.0091) 
Death 𝝁𝑫  
 Intercept 0.0008 (-0.0001, 0.0017) 
 Age  
    65-79 0.0105 (0.0094, 0.0116) 
    ≥ 80 0.0551 (0.0515, 0.0586) 
 Diabetes 0.0088 (0.0077, 0.0098) 
 Previous MI or stroke 0.0089 (0.0076, 0.0102) 
 Sex 0.0061 (0.0050, 0.0072) 
 Black 0.0030 (0.0021, 0.0039) 
 History of OASCVD 0.0027 (0.0017, 0.0038) 
 Atrial fibrillation 0.0093 (0.0056, 0.0129) 
 Kidney disease 0.0146 (0.0128, 0.0164) 
 Smoking  
    Past 0.0034 (0.0023, 0.0044) 




 Amlodipine 0.0003 (-0.0007, 0.0014) 
 Lisinopril -0.0004 (-0.0017, 0.0009) 
 𝜷𝑫𝑴   
 Intercept -0.0013 (-0.0049, 0.0023) 
 Age ≥ 65 0.0176 (0.0121, 0.0231) 
 𝜷𝑫𝑺   
 Intercept 0.0227 (0.0137, 0.0317) 
 Age* 0.0227 (0.0139, 0.0315) 
 𝜷𝑫𝑯   
 Intercept 0.0524 (0.0413, 0.0636) 
 Age ≥ 65 0.0206 (0.0071, 0.0341) 
*Excess hazard/absolute risk is the additional hazard/risk imparted by a risk factor compared to 
its reference group. 
⸶Statistically significant covariate from bagging 







Table 5. Area under the curve for the tuned IRHCM (70/30) 
 
Year 0 events 1+ events 2+ events 3+ events 4+ events 








(0.53, 0.65)  
0.63 
(0.54, 0.72) 




































Table 6. Area under the curve for IRHCM test set (70/30) 
 
Year 0 events 1+ events 2+ events 3+ events 








(0.50, 0.68)  





















CHAPTER 5: CONCLUSIONS 
This dissertation proposed a dynamic risk model that handles multi-type recurrent events 
with a dependent terminating event in a competing risk framework. A unique feature of the 
model is that it directly provides the baseline hazard for each type of recurrent event and the 
terminating event, and the additional hazard that each recurrent event confers to all other 
events. This quantifies positive and negative associations and relationships between all event 
types, recurrent and terminating. The baseline hazard is dynamically updated with each event 
occurrence, and is affected by event history (the number and types of past events) and 
covariates. In the first paper, we derived and formulated the model and then validated the model 
with a simulation study. The model was applied to the model to the Antihypertensive and Lipid-
Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) study and a procedure developed to 
assess goodness of fit of the model, therefore accomplishing aims 1 and 2 in the important arena 
of CVD.    
 We extended the model to incorporate risk factors for intrinsic hazards of the nonfatal 
CVD events MI, stroke and HF, and all-cause mortality (death) (IHCM 1) and further extended the 
model to incorporate risk factors for recurrent hazards, or for hazards imparted by antecedent 
nonfatal MI, stroke and/or HF (IRHCM). Heterogeneity of treatment effects on subgroups of 
patients was examined (IHCM 2). Goodness of fit for IHCM 1 and IRHCM was markedly improved 
for all individuals at baseline (0 events) and with 4+ events, and modestly improved for IRHCM 
for individuals with 1+ and 2+ events. Therefore, we conclude that CVD risk factors and 
antecedent CVD events are predictive of future CVD events and mortality, satisfying aim 3. 




handle missing covariates in longitudinal data would further augment the models and should be 
considered as an important future direction of this research.       
 Finally, IHCM 1 and IRHCM were stabilized and validated with a supervised learning 
approach. Bootstrap aggregated (bagged) training sets were utilized to stabilize the parameter 
estimates and construct 95% confidence intervals for every parameter using the standard 
deviations of the parameter’s bagged estimates. This in turn led to potential variable selection 
from stabilized parameter estimates with shrinkage of standard errors resulting in tighter 95% 
CI’s. Each training set’s estimated parameters was assessed for goodness of fit on its 
corresponding test set. IHCM 1 and IRHCM performed comparatively on test sets, which suggests 
that both models are stable and do not have the problem of overfitting, satisfying our 4th and 
final aim. 
 Our proposed multi-type recurrent events model has great potential to develop into a 
clinical risk assessment tool or risk score for CVD that incorporates both risk factors and event 
history and is tailored to the individual’s clinical profile, and provide head-to-head comparisons 
between treatment and therapeutic approaches for CVD. This would be of significant import in 
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